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Abstract 
Pentameric ligand gated ion channels (pLGICs) form a large family of integral membrane proteins 
involved in fast signal transduction at synapses. They are located at the postsynaptic side where they 
convert a chemical signal triggered by release of neurotransmitters from the presynaptic cell into the 
synaptic cleft to an electrical signal, in the postsynaptic cell. Dysfunction of these receptors can cause 
severe diseases such as Alzheimer’s disease, epilepsy or schizophrenia. Since their discovery in the 
1970ies they have been intensively studied with biochemical and electrophysiological methods, 
investigating both structure and function. 
Forty years after their discovery, the structure of the acetylcholine binding protein (AChBP) was solved 
which is a homologue of the N-terminal extracellular domain of a pLGIC. Recently, structures of the 
procaryotic homologues GLIC (from Gloebacter violaceus) with bound ligand and ELIC (from Erwinia 
chrysanthemi) without ligand were determined.Pentameric ligand gated ion channels are composed of 
an extracellular, ligand-binding domain, predominantely consisting of β-strands and a transmembrane 
pore domain consisting of α-helices. Upon binding to a specific agonist in a conserved part of the 
extracellular domain, a conformational change occurs which is transduced to the transmembrane part 
and leading to the opening of the ion channel. This rearrangement is transferred via a conserved 
interface between the two domains. To gain more insight into this important gating mechanism, two 
different strategies involving both - structural and functional investigations, were performed in this work.  
Towards this goal, specific protein binders were selected by Ribosome and Phage Display for the above 
mentioned prokaryotic homologues GLIC and ELIC. Such binders have the potential to act as 
crystallization chaperones. Additionally they could stabilize the channel in a specific conformation or 
influence its functional properties. For GLIC, single chain variable fragments (scFvs) and designed 
ankyrin repeat proteins (DARPins) were successfully selected from synthetic Phage and Ribosome 
Display libraries. These binders were further analyzed to characterize their binding specificity, their 
affinity and assess their potential impact on structure. Twelve binders are highly specific and show high 
affinity to GLIC.  Attempts to co-crystallize the binders with GLIC have not been successful.  In vivo 
experiments to evaluate the effect of these binders on the function of the channel revealed no significant 
binding. In the case of ELIC, 33 DARPins were selected by Ribosome Display and 12 nanobodies, were 
selected from a Phage Display library originating from immunized alpacas. The majority of these binders, 
have adverse biochemical properties such as aggregation and unspecific binding. 
In a second approach to examine the gating mechanism of these channels, mutations of residues 
located in the conserved interface between the extracellular and transmembrane domain were 
characterized by two-electrode voltage clamp experiments. Several amino acids in the β1-β2 loop, β6-
β7 loop, the β10-α1 linker and the α2- α3 loop of both homologues were mutated to alanine and 
expressed in Xenopus laevis oocytes. The oocytes were subjected to two-electrode voltage clamp 
electrophysiology and the evoked currents were compared to oocytes expressing the corresponding 
wild type protein. To ensure that the proteins are properly folded and correctly located at the plasma 
membrane a surface assay was performed, using an antibody targeting a tag fused to the expressed 
protein. Based on the electrophysiological data and the subsequent oocyte surface assays, several 
residues, relevant for the gating mechanism, were identified. 
Our results show that in both homologues the corresponding mutations have a similar effect, which 
emphasizes the high conservation of this mechanism. Similar studies with eukaryotic nAChR revealed 
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a comparable behavior, underlining the conservation of the gating mechanism among the family. 
Therefore our results underline the relevance of the prokaryotic homologues GLIC and ELIC as model 
system. 
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Zusammenfassung 
Pentamere liganden-gesteuerte Ionenkanäle (pLGICs) bilden eine grosse Familie von integralen 
Membranproteinen die in der schnellen Signalübertragung an Synapsen involviert sind. Sie befinden 
sich in der postsynaptischen Membran der Nervenzellen wo sie ein chemisches Signal, das durch die 
Ausschüttung von Neurotransmittern aus der präsynaptischen Zelle in den synaptischen Spalt ausgelöst 
wird, in ein elektrisches Signal umwandeln. Fehlfunktionen dieser Rezeptoren können schwerwiegende 
Krankheiten wie Alzheimer, Epilepsie oder Schizophrenie auslösen. Seit ihrer Entdeckung in den 1970er 
Jahren wurden sie daher intensiv mit Hilfe biochemischer und elektrophysiologischer Methoden 
erforscht um ihre Funktion und Struktur zu untersuchen. 
Vierzig Jahre nach ihrer Entdeckung wurde die Struktur des acetlycholin-bindenden Proteins (AChBP) 
aufgeklärt, welches ein Homolog der N-terminalen extrazellulären Domäne eines pLGICs ist. Kürzlich 
wurden die ersten Strukturen der prokaryotischen Homologe GLIC (aus Gloebacter violaceus) mit 
gebundenem Liganden und jene von ELIC (aus Erwinia chrysanthemi) ohne den Liganden, gelöst. 
Pentamere liganden-gesteuerte Ionenkanäle bestehen aus einer extrazellulären Domäne, welche 
mehrheitlich aus β-Strängen besteht an die die Liganden binden, sowie aus einer transmembranen 
Porendomäne die von α-Helixen dominiert wird. Durch das Binden spezifischer Agonisten an eine 
hochkonservierte Region der extrazellulären Domäne wird eine konformationelle Änderung ausgelöst, 
welche an die Transmembrandomäne übertragen wird und so die Öffnung des Ionenkanals bewirkt. 
Diese Reorganisation wird durch eine konservierte Schnittstelle übertragen, die sich zwischen den zwei 
Domänen befindet. Um mehr über diesen wichtigen Mechanismus zu erfahren, wurden zwei 
unterschiedliche Strategien, unter Einbezug von strukturellen und funktionellen Untersuchungen, 
verfolgt. 
In einem ersten Schritt wurden spezifische Proteinbinder für die obengenannten prokaryotischen 
Homologe GLIC und ELIC mit Ribosomen und Phagen Display selektioniert. Solche Binder können als 
Kristallisationshelfer agieren, die Kanäle in einer definierten Konformation stabilisieren oder einen 
Einfluss auf die Funktion haben. Es wurden erfolgreich scFv-Fragmente und DARPins für GLIC mit 
Phagen Display beziehungsweise Ribosomen Display selektioniert und ihre Spezifität, Affinität und 
Einfluss auf Struktur und Funktion analysiert. Obwohl 12 dieser Binder sehr spezifisch und mit hoher 
Affinität an GLIC binden, veränderten sie weder die Kristallisationseigenschaften des Kanals noch 
konnte einen Einfluss auf die Funktion gemessen werden. Für ELIC zeigten die meisten der 33 
DARPins, die mit Hilfe des Ribosomen Displays selektioniert wurden und der 12 Nanobodies, die durch 
die Immunisierung von Alpakas gewonnen und mit Hilfe des Phagen Displays identifiziert wurden, 
unerwartete biochemische Eigenschaften wie Aggregation und Unspezifität. 
Eine andere Möglichkeit den Aktivierungsmechanismus dieser Kanäle zu untersuchen, ist die Mutation 
von Aminosäuren die sich in der konservierten Schnittstelle zwischen der extrazellulären und der 
Transmembrandomäne befinden. Mehrere Aminosäuren im β1-β2 Loop, im  β6-β7 Loop, im β10-α1 
Linker und im α2- α3 Loop beider Homologe wurden zu Alanin mutiert und in Oozyten des 
Krallenfrosches (Xenopus laevis) exprimiert. Die Oozyten wurden einem elektrophysiologischen 
Experiment unterzogen um die entstehenden Ströme nach Ligandenapplikation zu messen, welche 
dann mit denjenigen des Wildtyps verglichen wurden. Um Sicherzustellen, dass die Kanäle trotz 
Mutation korrekt gefaltet sind und an der Oozytenmembran lokalisiert sind, wurde ein Oberflächentest 
durchgeführt, wobei ein Antikörper einen mit den exprimierten Homologen fusionierten Tag bindet. 
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Durch obengenannte Experimente konnten mehrere Aminosäuren identifiziert werden,  welche für die 
Aktivierung wichtig sind. Es wurde gezeigt, dass die Mutationen in beiden Homologen einen ähnlichen 
Effekt haben was die Konservierung dieses Prozesses unterstreicht. Ähnliche Studien mit 
eukaryotischen nAChR zeigen ein vergleichbares Verhalten, was die Konservierung des 
Aktivierungsmechanismus innerhalb der Familie unterstreicht und die Verwendung von GLIC und ELIC 
als gutes Modellsystem aufzeigt. 
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1.1 Electrical and chemical synapses 
The brain is the primary organ of our and other animal’s nervous system. Communication between the 
neurons is mandatory for function and mediated by cell-cell interactions, called synapses (greek, syn: 
together and haptein: grasp, touch). In general there are 2 different types of synapses (Figure 1), 
chemical synapses and electrical synapses [1]. 
 
 
Figure 1 Signal transmission at chemical and electrical synapses. 
A) Chemical synapse. An action potential in the presynaptic cell causes the depolarization of the membrane which 
leads to the influx of calcium ions through voltage-gated calcium channels (VGCCs). Vesicles filled with 
neurotransmitter fuse with the presynaptic membrane and release their content into the synaptic cleft. The binding 
of neurotransmitters to different receptors in the postsynaptic membrane, can have various effects (as a change of 
the membrane potential, initiation or termination of gene expression and the initiation of biochemical signaling 
cascades). Subsequently the neurotransmitter has to be removed from the synaptic cleft by re-uptake or enzymatic 
degradation etc. B) Electrical synapse. The interior of the two cells are connected by gap junctions, which are 
clusters of intercellular channels. An action potential in the presynaptic cell causes the depolarization of the 
membrane of the postsynaptic cell, but with a certain attenuation depending on the membrane resistance. 
Compared to the chemical transmission, the electrical transmission is faster and bidirectional. Figure adapted from 
[1]. 
 
Whereas at chemical synapses, the cells approach each other at a distance of 20-40 nm, the cells in 
electrical synapses are separated by only about 3.5 nm. In electrical synapses, the cytoplasms of two 
adjacent cells are connected via gap junctions, which are clusters of intercellular channels [2, 3]. These 
channels are formed by 2 hexameric hemichannels and establish a bidirectional passage for the flow of 
ions such as calcium [4]. An action potential in the presynaptic cell causes the depolarization of the 
adjacent cell, but with a certain attenuation depending on the membrane resistance. The electrical 
synapses are mostly located in part of the nervous system that is involved in fast responses.  
The chemical synapses arose earlier in evolution and they are also important in the communication of 
unicellular organisms and play a role in quorum sensing in bacteria, the detection of bacterial density 
[5]. In the nervous system an action potential in the presynaptic cell leads to the depolarization of the 
membrane and subsequent influx of calcium ions into the cell through voltage-gated calcium channels 
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(VGCCs). Vesicles, filled with neurotransmitter, deplete into the synaptic cleft by exocytosis. Different 
receptors, located in the membrane of the postsynaptic cell, bind these molecules and cause a change 
in membrane potential, initiation or termination of gene expression or the initiation of biochemical 
signaling cascades. Afterwards, the neurotransmitter has to be removed from the synaptic cleft, by re-
uptake or enzymatic cleavage [3, 6, 7]. Many of the receptors, involved in signal transduction in 
synapses, are ligand-gated ion channels that are part of three subfamilies: nucleotide-gated ion 
channels, ionotropic glutamate receptors and pentameric ligand-gated ion channels. 
 
1.2 Pentameric ligand-gated ion channels 
1.2.1 Structure of pentameric ligand-gated ion channels 
Pentameric ligand-gated ion channels (pLGICs) or Cys-loop receptors constitute a large family of 
integral membrane proteins, which transduce signals in the form of ions across cell membranes after 
binding to a specific neurotransmitter released by the adjacent pre-synaptic cell into the synaptic cleft. 
They therefore translate a chemical signal into an electrical one. pLGICs consist of an extracellular 
ligand binding domain (ECD) and a transmembrane ion channel. Cys-loop receptors are pentameric 
proteins and have a conserved loop between the β6- and β7-sheet which is bracketed of two cysteines. 
This receptor superfamily can be divided into excitatory (activated by acetylcholine or serotonin) and 
inhibitory receptors (activated by glycine, glutamate or GABA), which are cation- or anion-selective, 
respectively [8-10]. 
 
 
Figure 2 Ribbon representation of an acetylcholine binding protein. 
The N-terminal α-helix (blue) is followed by a β-sandwich, consisting of 10 β-strands. Disulfide bonds are colored 
in green. In a complete ion channel the C-terminus would be connected to the transmembrane α-helices. Figure 
adapted from [11]. 
 
The subfamily of nicotinic acetylcholine receptors (nAChRs) are present at the neuromuscular junction 
and in neuronal tissues [12, 13]. Despite investing large efforts, to date no crystal structure of a nicotinic 
acetylcholine receptor could be determined [14-17]. In 2001 however, Brejc and colleagues [11] 
determined the structure of the acetylcholine-binding protein (AChBP) from Lymnaea stagnalis, 
originally discovered by Smit and colleagues [18], which is a homologue of the N-terminal extracellular 
domain of a Cys-loop receptor. In the following years, several structures of acetylcholine-binding 
proteins, with and without agonist were solved [19-22]. These structures have revealed the fold of the 
protein, containing an N-terminal α-helix and a β-sandwich, consisting of an inner β-sheet with 6 and an 
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outer β-sheet with 4 strands. In general the AChBP shows an immunoglobulin like fold and the structures 
gave insight into the agonist binding site (Figure 2). 
In 2005, the structure of the membrane-associated acetylcholine receptor (AChR) from the Torpedo 
electric ray was solved by electron microscopy and, despite the low resolution, it allowed for the 
comprehension of general structural features and provided initial insight into potential gating 
mechanisms [23]. Surprisingly, in the same year, benefiting from the increased knowledge of genomic 
data, prokaryotic homologues of Cys-loop receptors were identified [24]. Regardless of less than 30% 
sequence identity compared to eukaryotic family members, they show conservation in their overall 
structure and in functional characteristics such as desensitization, ion selectivity and the sensitivity to 
several chemical compounds [25-31]. However, in contrast to eukaryotic receptors, they all lack the 
cysteines in the β6-β7 loop, and form homopentamers. Only few years after the discovery of prokaryotic 
homologues, X-ray structures of the cation-selective homologue ELIC, from the phytopathogenic 
bacterium Erwinia chrysanthemi, and GLIC, from the cyanobacterium Gloebacter violaceus, were solved 
with a resolution of 3.3 Å and 2.9 Å, respectively (Figure 3). Both bacterial homologues show conserved 
tertiary and quaternary structures. The proteins are homopentamers, the extracellular domain consists 
of 10 β-strands and it forms a tube that is 60 Å high and 90 Å wide. The transmembrane part of the 
protein consists of 4 α-helices per subunit, with α-helix 2 of each subunit lining the pore, whereas the α-
helices 1, 3 and 4 shield the channel. Along the pore axis from the extracellular side three consecutive 
rings of hydrophobic amino acids form the channel gate, followed by 2 rings of polar and 1 ring of 
charged residues that interact with ions and influence the selectivity. Additionally charged residues in 
the extracellular part of the pore also contribute to ion selectivity by making the electrostatic potential 
negative. The selectivity of pLGICs is not for a specific ion but it is based on the charge of permeating 
ions. Both GLIC and ELIC are known to be cation-selective.[26, 27, 32]. 
The prokaryotic homologues GLIC and ELIC lack disulfide bridges and do not contain a cytoplasmic 
domain between the α-helices 3 and 4 that is present in eukaryotic proteins. A eukaryotic homologue 
GluCl from Caenorhabtitis elegans, whose structure was solved at a resolution of 3.3 Å, contains the C-
loop and the Cys-loop disulphides, conserved in eukaryotic family members [10]. Further high resolution 
X-ray structures of eukaryotic Cys-loop receptors were solved in the following years [33, 34]. The 
prokaryotic homologue ELIC was crystallized in a presumably non-conductive conformation, since the 
pore is blocked by hydrophobic side chains [32], whereas GLIC and GluCl were crystallized with bound 
ligands (protons in case of GLIC and glutamate plus ivermectin in case of GluCl) and show a potential 
conductive conformation of the channel as underlined by the larger pore diameter and the tilt of the C-
terminus of the α2-helices from the channel axis [10, 26, 27]. 
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Figure 3 Ribbon representation of ELIC and GLIC. 
A) ELIC. View from within the membrane with the extracellular domain above. The cell membrane is indicated by 
grey bars. Below, the top view from the extracellular side is shown. B) GLIC. View from the side with the extracellular 
domain above, the cell membrane is indicated by grey bars. Below, the top view from the extracellular side is shown. 
Whereas ELIC was crystallized in a potential non-conductive conformation, GLIC is supposed to be in a conductive 
state. Adapted from [26, 32]. 
 
Another crystal structure of GluCl, cocrystallized with ivermectin and the open channel blocker 
picrotoxin, reinforced the open channel hypothesis, since picrotoxin was found to occlude the pore. A 
cysteine mutant of GLIC, where residues in the loop between the α-helices 2 and 3 were crosslinked to 
residues located in the β6- β6 loop, shows a so-called “locally closed” conformation with a smaller pore 
diameter, which partly resembles the non-conductive pore of ELIC [35]. Recently the structure of GLIC 
was determined at neutral pH. In this structure, which resembles the locally closed conformation, the C-
terminal part of the α2-helix is tilted thereby blocking the pore whereas the α2- α3 loop has changed its 
conformation [35, 36]. Furthermore, a structure of GluCl in absence of ivermectin in a supposedly non-
conductive conformation was published, which resembles the structure of ELIC [37]. Recently the 
structure of the glycine receptor GlyR in different states (agonist-bound, antagonist-bound and 
desensitized or partially open) was determined by electron cryo-microscopy [38]. Although several 
structures of pLGICs are now available, a definitive assignment to the different states of the receptor 
remains uncertain. Although the above mentioned nAChR structure represents a presumably closed 
conformation since no agonist was added [23], the conformation of its α2-helices appears to be similar 
to GLIC and GluCl. Further investigations of the ligand bound nAChR revealed only slight changes in 
the pore and it was thus questioned how the available structures can be assigned to functional 
conformations [39]. Despite these discrepancies, all family members show similar overall structures and 
it is likely that they might share a comparable activation mechanism. 
Pentameric ligand-gated ion channels are activated by different agents, called ligands or agonists. ELIC 
is activated by primary amines [40] whereas GLIC responds to protons [41]. The anion-selective GluCl 
from Caenorhabtitis elegans is activated by glutamate and ivermectin [10]. The ligand binding pocket of 
pLGICs lies at the interface between two subunits in the extracellular domain and the structural 
rearrangement upon binding a ligand was studied in the acetylcholine binding protein (AChBP). The C-
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loop, capping the binding site, showed the biggest structural rearrangements. Upon binding of agonist, 
the loop closes the binding site via a 7 Å movement, whereas the binding to an antagonist appears to 
push the loop outwards [19]. After agonist binding, structural rearrangements cause the opening of the 
pore in the transmembrane part of the protein. It is supposed, that this conformational change is 
transduced via a conserved interface composed of loops of the extracellular as well as of the 
transmembrane domain. The “principal pathway of gating” postulated by Lee and colleagues, involves 
conserved residues (arginines and glutamates) at the extracellular domain, which interact with 
conserved positions at the top of the pore domain. The β10- α1 linker (or pre-M1 linker) is supposed to 
be coupled to the α2-α3 loop (or M2-M3 loop) via the β1-β2 loop [42]. The acetylcholine receptor shows 
interactions of residues from the β1-β2 loop and the β6-β7 loop (or Cys-loop) as well with residues 
located at the β10-α1 linker and the α2-α3 loop indicating another signal transduction pathway via the 
Cys-loop, the “Cys-loop pathway” [43]. In Figure 4 the corresponding loops of the domain interfaces of 
GLIC and ELIC are shown (see attached publication “Signal transduction at the domain interface of 
prokaryotic pentameric ligand-gated ion channels”).  
Chimeras of the acetylcholine binding protein and the pore domain of the serotonin receptor only showed 
activation, when the β1-β2 loop, the β6-β7 loop and the β8-β9 loop, located in the extracellular part, 
were exchanged with the corresponding loops of the homologue forming the pore, which underlines the 
significance of the coupling of these loops with the aside placed α2-α3 loop from the transmembrane 
part for function [44]. 
 
 
Figure 4 Domain interface of GLIC and ELIC. 
A) Domain interface of ELIC, shown as Cα-trace. The β1-β2 loop, β6-β7 loop, β8-β9 loop and the β10- 
α1 linker from the extracellular domain as well the α2-α3 loop from the transmembrane part are colored. 
B) Domain interface of GLIC, shown as Cα-trace. The β1-β2 loop, β6-β7 loop, β8-β9 loop and the β10- 
α1 linker from the extracellular domain as well the α2-α3 loop from the transmembrane part are colored. 
Image adapted from the publication “Signal transduction at the domain interface of prokaryotic 
pentameric ligand-gated ion channels”. 
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1.2.2 Activation of pentameric ligand-gated ion channels 
The activation of pentameric ligand-gated ion channels upon binding to a specific agonist has been 
investigated for a long time and models, based on enzyme kinetics were established. A two-state model 
describing the processes of receptor activation has been established in the late fifties by Del Castillo 
and Katz and includes a closed agonist-receptor complex (Figure 5). The binding of the agonist (A) to 
its receptor (R) present in a closed conformation, is fast and only depends on the binding affinity of the 
agonist to the resting state. Subsequently the closed agonist-bound receptor (AR) undergoes a transition 
resulting in an open channel conformation (AR*). This transition is described by an equilibrium constant, 
called efficacy, which is the capability of the ligand to open the channel [45]. Diverse agonists differ in 
their efficacy, the ability to promote channel opening. 
 
 
Figure 5 Model to explain activation of a receptor. 
The closed receptor (R) binds its agonist (A) with an association rate constant k+1.and subsequently undergoes a 
transition leading to channel opening (AR*). k-1 is the agonist dissociation constant, β the channel opening and α 
the channel closing rate constant. Adapted from [46]. 
 
Preliminary experiments with frog endplates displayed a cooperative binding behavior of the receptors 
to the agonist, which has led to the assumption that these proteins possess numerous binding sites, 
which are allosterically linked. Because the agonist binding to an AChBP does not show any 
cooperativity, the above shown model of the AChBP is only partly useful to describe the changes 
underlying the highly cooperative channel activation. Another model for activation, proposed by Monod 
and colleagues suggests, that even in the absence of a ligand the receptor can be present in an active 
conformation and it considers the possibility of more than one agonist bound to the receptor describing 
cooperativity (Figure 6) [47].  
 
Figure 6 Model according to Monod, Wyman and Changeux. 
The receptor (R) can exist in the inactive and active (R*) form even in absence of an agonist (A). This model also 
takes into account that more than one agonist can be bound to the receptor. Adapted from [47]. 
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Upon prolonged exposure to the agonist, pLGICs become refractory to activation, called desensitization. 
Although a ligand remains bound, the channels enter a non-conductive conformation. In Figure 7, a 
patch clamp recording of ELIC expressed in Xenopus laevis oocytes shows desensitization upon long 
exposure of the agonist cysteamine. Even though the agonist is applied for more than 30 seconds, after 
only 1 second the evoked current decreases rapidly. Eventually only small bursts of single channels can 
be observed [40]. In synapses, neurotransmitters are removed from the synaptic cleft by reabsorption 
or enzymatic digestion [3, 6, 7] within milliseconds, whereas the desensitization of ELIC, for example, 
happens within seconds and it’s therefore much slower. It was also observed that certain eukaryotic 
pLGICs such as the α7-nAChR desensitize much faster. Thus desensitization may have a biological 
relevance and can play a role in memory and learning processes [48].  
 
 
Figure 7 Patch clamp recording of ELIC expressed in X. laevis oocytes. 
Upon long exposure to the agonist cysteamine at a concentration of 5 mM (black bar) ELIC desensitizes, which is 
manifested in the current decay. The vertical black bar corresponds to 10 pA and the horizontal bar to 5 seconds. 
Adapted from [40]. 
 
Considering the allosteric, cooperative mechanism and the desensitization of pLGICs, a general 
reaction model describing a ligand-gated ion channel binding 2 ligand molecules was established 
(Figure 8). The different conformations of the receptor with and without agonist are shown and it was 
postulated, that even in absence of the agonist, the receptors can adopt a desensitized conformation 
[49]. 
 
 
Figure 8 Reaction mechanism of a receptor binding two agonist molecules. 
Different states of the receptor with or without ligand are depicted. S: closed, non-conductive state. O: open, 
conductive state. D: desensitized state. β: channel opening rate constant. α: channel closing rate constant. δ: entry 
into desensitized state. k-1: ligand dissociation rate constant. Figure adapted from [49]. 
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In fact, Corringer and colleagues showed, that up to 1 % of the nicotinic acetylcholine receptors without 
ligand are present in the desensitized state [50]. Furthermore, a recent study suggested the existence 
of multiple conformations for a given state and proposed asymmetric conformational changes in 
homopentamers. For ELIC it is was also proposed that, during the transition between states, the 
conformational changes are not evenly distributed among the different regions of the protein [51]. 
To understand the allosteric gating mechanisms of these receptors at the molecular level, structural 
knowledge of the diverse states are required. Distinct conformations of the channels are observed in 
the ELIC and GLIC structures. Agonist binding to the extracellular domain causes a conformational 
change, which leads to the opening of the channel (gating) in the transmembrane part in less than a 
millisecond. The comparison of the structures of GLIC and ELIC proposes an anticlockwise twist of each 
extracellular subdomain and a tilt of the α2-helices which line the pore [26, 27, 52]. A very recent study 
of the glycine receptor (GlyR) in different conformations proposes an iris-like expansion and an 
anticlockwise rotation of the transmembrane α-helices as well [38]. Upon long exposure to the specific 
agonist, the channels get into an unresponsive, desensitized state. It is debated whether the crystal 
structure of GLIC corresponds to a desensitized state and the structure of ELIC to a nonfunctional 
conformation [25, 30, 39]. To learn more about the gating of pLGICs, it is necessary to identify residues 
that are important for conformational changes between different channel conformations. At the same 
time it is crucial to assign the different structures to the different states, and to determine structures of 
the same homologue in different conformations. With the help of specific protein binders which detect 
certain states of the channels, different conformations could be stabilized and ideally crystallized. 
 
1.3 Specific protein binders 
Specific protein binders can be used as chaperones for crystallization or as modulators of the function 
of the targeted protein. Several specific protein binders, selected in vivo or in vitro, have already been 
successfully used for other membrane transport proteins, to influence the protein function in vivo or to 
prevent ligand binding to the protein [53-55]. Protein binders that are used as crystallization chaperones 
are of great interest in the field of structural biology as reviewed in [56]. These protein ligands enlarge 
the hydrophilic part of membrane proteins and thus generate a larger surface for possible crystal 
contacts. Furthermore a binder can reduce the flexibility of certain regions or loops, which may prevent 
efficient crystallization or stabilize the target protein in a defined conformation [57]. 
So far, the most successful binding proteins are antibodies and their fragments (Fab fragments, scFvs 
and nanobodies, Figure 9). Antibodies are produced by B-lymphocytes that are differentiated into an 
effector B-cell, upon exposure to an immunogenic intruder (bacterium, virus, foreign proteins) and upon 
activation by a T helper cell. For structural and functional studies, purified monoclonal antibodies are 
needed at high concentrations. Since B-lymphocytes, isolated from the blood of the animal which was 
immunized with the target protein (the immunogenic substance), eventually die in culture, they need to 
be immortalized. The fusion with a lymphocyte tumor cell, forming a hybridoma cell-line, results in cells, 
which produce the desired monoclonal antibody and which are able to propagate infinitely. 
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Figure 9 Schematic representation of antibodies. 
Left: schematic representation of a conventional antibody (ca. 150 kD), a Fab fragment (ca. 50 kD) and a scFv 
fragment (ca. 25 kD). Right: schematic representation of a heavy chain antibody and a nanobody (ca. 15 kD). Figure 
adapted from creative biolabs. 
 
The complementary determining regions (CDRs) in the variable part of the antibodies form the antigen 
binding site. In Figure 10, a Fv fragment with highlighted CDRs is shown. Both variable domains from 
the heavy and the light chain (VH and VL, respectively) have 3 CDRs which interact non-covalently. The 
remainders of the variable part provide structural support and also affect the CDR conformation and 
orientation and therefore increase the binding diversity [58, 59] [60]. 
 
 
Figure 10 Ribbon representation of a Fv fragment 
Ribbon representation of a Fv fragment seen from the antigen perspective. Dark blue) variable part of the heavy 
chain (VH), light blue) variable part of the light chain (VL). Yellow) CDR1, orange) CDR2, red) CDR3. Figure adapted 
from [58]. 
 
Antibody fragments only consisting of its variable parts, show better biochemical characteristics in terms 
of expression yields and stability. They can be obtained from mature antibodies by digestion with certain 
proteases (pepsin, papain) or they are recombinantly expressed in bacteria or yeast [61]. For identifying 
the fragments for the recombinant production, the DNA coding for the desired antibody fragment has to 
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be known. For that purpose, B-lymphocytes, expressing the corresponding antibody, are collected and 
the DNA encoding for the antibody fragment is PCR-amplified with specific primers and cloned into a 
Phage Display library. This library is subjected to 1-2 rounds of Phage Display and the specific binders 
for the target protein are subsequently selected [62, 63]. 
Twenty years ago, the structure of the cytochrome c oxidase, co-crystallized with an antibody fragment 
was solved [64]. Further membrane protein structures bound to specific antibody fragments (Fab or Fv 
fragments), could be determined in the following years [10, 65-68]. In the late 80’s of the last century, a 
group of students during a practical course in Brussels, by chance discovered antibodies that were 
smaller than the known immunoglobulins. This phenomena was investigated more thoroughly by 
Hamers and Casterman who discovered that these newly detected antibodies only consist of a heavy 
chain and that these chains lacking the constant domain of the antigen binding part of the molecule and 
thus only have a single antigen binding domain per chain (Figure 9). These heavy chain only nanobodies 
appear in many camelids, ratfishs and in nurse sharks [69, 70], but investigations revealed an 
independent evolutionary background of different heavy chain antibodies [71]. The binding epitopes of 
these heavy chain antibodies, also named nanobodies or VHH, corresponds to the variable part of the 
heavy chain of antibodies. Because of the small size (about 15 kD) and the long CDR3 loop (16-18 
amino acids versus 12 amino acids in human antibodies) they are supposed to be able to recognize 
cavities as binding epitopes [62, 72, 73]. Several membrane protein structures determined with the help 
of these heavy chain antibody fragments (nanobodies) have been published recently [34, 74-77]. 
Synthetic repeat proteins such as DARPins [78] that are selected in vitro by Ribosome Display, have 
become promising alternatives to antibodies in structural biology and for functional investigations. They 
are based on naturally appearing ankyrin proteins, which mediate protein-protein interactions in all 3 
kingdoms of life [79, 80]. DARPins consist of several internal repeats, capped by an N- and a C-terminal 
domain (Figure 11). They have successfully been selected for various membrane proteins such as the 
bacterial multidrug exporter AcrB [53], the Na+ citrate exporter CitS  [81], the neurotensin receptor 1 [82] 
and the multidrug ABC-transporters  MsbA and LmrCD [54, 57]. 
 
 
Figure 11 Cartoon representation of a DARPin. 
Left: The N-terminal (green) and C-terminal (cyan) domains can cap a variable amount of internal repeats (blue). 
Right: cartoon representation of a MPB binding DARPin molecule (off7) consisting of 3 internal repeats (N3C 
DARPin). Randomized positions of this DARPin library are shown as red sticks. Figure adapted from [78]. 
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1.4 Aim of thesis 
Although, ligand gated ion channels have been studied for more than 40 years, the detailed mechanism 
of channel gating remains unclear. Upon binding to an agonist in the extracellular domain, the C-loop 
caps the binding site, followed by structural rearrangement of the transmembrane part leading to pore 
opening. To understand the allosteric mechanism, a comparison of the structures of the receptors in 
different conformations is required. Several structures of family members were solved in the last years, 
including the high resolution X-ray structures of the prokaryotic homologues GLIC and ELIC, and the 
eukaryotic GluCl. However in all cases only the structure in a single conformation was available. 
Whereas GLIC and GluCl were crystallized with bound agonist in a presumably open conformation, the 
structure of ELIC supposedly shows a closed state of the pore. To gain deeper insight into the function 
of these channels, it was tried to determine the structure of GLIC and ELIC in a different conformation. 
Since previous approaches to crystallize GLIC at low proton concentration in a closed state and ELIC 
with a bound agonist were unsuccessful, it was attempted to select specific protein binders, which may 
act as crystallization chaperones and may stabilize the protein in a different conformation. In a second 
set of experiments, this work contributed to a larger study in the group that aimed at a thorough 
investigation of the gating mechanism by characterizing the role of residues located at the interface 
between the extracellular and the transmembrane domain of the channels. This region is known to play 
an important role in the transduction of structural changes between the two domains following agonist 
binding. The function of the channel mutants was characterized by two-electrode voltage clamp 
electrophysiology and the structure of certain mutants were determined by X-ray crystallography to 
investigate the impact of the mutation on the structure. 
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2.1 Selecting specific protein binders 
Specific protein binders can be used as auxiliary proteins for the crystallization of their target protein. 
They can bind to loops or other flexible regions of their target, thereby reducing its flexibility and 
enlarging the soluble part available for crystal contacts. Binders can stabilize trap the target protein in a 
certain conformation or have an impact on protein function [53, 55-57]. To generate specific binding 
proteins for GLIC or ELIC three different classes of binding proteins were used. i) scFvs (single chain 
variable fragments) which were selected in vitro by Phage Display. ii) DARPins, which were selected in 
vitro by Ribosome Display and iii) nanobodies which were selected in vivo by immunization of alpacas 
followed by Phage Display. After the selection procedure the binders were characterized by ELISA, size 
exclusion chromatography (SEC) and surface plasmon resonance (SPR). For a better understanding of 
the gating mechanism of pentameric ligand gated ion channels, the structure of the targeted proteins 
has to be determined in different conformations. GLIC was crystallized at high proton concentrations 
and the structure solved in a presumably conductive state [26]. Since all the selection experiments with 
GLIC were conducted at neutral or slightly basic pH, we expected the channel to be in a nonconductive 
state and the binders to specifically recognize this conformation and potentially stabilize it for 
crystallization. The Ribosome Display selection with ELIC was performed with the target protein bound 
to its agonist and antagonist, propylamine and acetylcholine, respectively, and therefore it was assumed 
that ELIC may be in a desensitized or closed state depending on the bound ligand. This attempt has led 
to the identification of only a few unspecific binders. Therefore an additional selection procedure without 
any ligand was performed. In a second strategy, alpacas were immunized with ELIC, followed by Phage 
Display with ligand free ELIC, which allowed the identification of several nanobodies targeting ELIC. 
 
2.1.1 Construct preparation 
To select for specific binders with various display techniques and for structural analysis, high 
concentrations of detergent purified target protein are needed. The pentameric ligand gated ion 
channels GLIC and ELIC can be recombinantly produced in E.coli, extracted from the bacterial 
membranes with detergent and purified by metal chelate affinity chromatography (IMAC), via a fused a 
His10 tag. The DNA coding for ELIC was cloned in a pET26 vector, and the protein was expressed upon 
induction of transformed bacteria grown in minimal media with Isopropyl-β-D-thiogalactopyranosid 
(IPTG). Initially GLIC, cloned in the same vector, was expressed in cells grown in Terrific Broth (TB) 
medium in shaker flasks. Since the obtained yields were low in comparison to ELIC (0.05-0.3 mg/L 
versus 0.5-1 mg/L), a different expression strategy for GLIC has been established. The DNA coding for 
GLIC was cloned in a pBAD vector, where expression of the gene of interest is under the control of the 
arabinose promoter. Like in the original construct, the protein is preceded by an N-terminal PelB signal 
sequence, a His10-tag, the fusion protein MBP and a 3C cleavage site (Figure 12). 
 
 
Figure 12 Construct of GLIC and ELIC. 
The construct of GLIC and ELIC (red) contains an N-terminal PelB signal sequence (blue), followed by a His10-tag 
(light blue), MBP as fusion protein (green) and a HRV 3C cleavage site (light green). 
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Compared to the arabinose-induced overexpression, the disadvantage of the IPTG induced T7 
expression system lies in residual expression of the target protein even in the absence of inducer. This 
can result in reduced cell growth and lower protein yields. Using a pBAD expression system, this 
problem could be circumvented [83]. The new expression system was tested in 5 ml TB culture with 
MC1061 cells containing a vector coding for GLIC. Cells were supplied with different arabinose 
concentrations for induction. After the overnight expression, the cells were lysed and the protein 
extracted with DDM. A western blot analysis revealed that the induction with 0.04 % arabinose gives the 
highest protein yields after extraction (Figure 13). 
 
Figure 13 Western blot with expression test of GLIC in a pBAD vector. 
Expression of GLIC in 5 ml cultures in an arabinose inducible system compared to the previously used IPTG 
inducible T7 system. After induction with different arabinose concentrations, the cells were harvested, lysed (L).  
Subsequently the MBP-GLIC fusion protein was extracted with DDM and insoluble parts were removed by 
centrifugation (E). The expression yields were compared with the expression levels of the pET-vector. The fusion 
protein was detected with an anti His10-antibody. 
 
Although the scale-up of the expression of GLIC with the pBAD system from the 5 ml culture to a 9 l 
fermenter culture was not not linear and the protein yields per cell are slightly lower than expected, for 
subsequent experiments the expression in fermenter was preferred over the shaker flasks. This is 
because in the fermenter the cells can grow to higher maximal cell density due to better aeration (OD 
2-4 in flasks versus OD 15-20 in the fermenter) and thus more protein per liter of culture can be produced 
in that way. After expression of the protein over night at 18 °C, the cells were harvested, lysed and the 
protein extracted with 1 % DDM. After centrifugation of the sample to separate the extracted protein 
from non-lysed cells and cell debris, GLIC was affinity purified by a Ni-NTA- chromatography. 
Afterwards, the His-MBP fusion was cleaved with the HRV 3C protease during dialysis to lower the 
imidazole concentration, removed by binding to Ni-NTA resin and the membrane protein was subjected 
to size exclusion chromatography. ELIC, expressed in minimal medium, was purified similar to GLIC but 
instead using the detergent UDM. In Figure 14 a size exclusion chromatogram of a Superdex S200 
column of both GLIC and ELIC is shown. The peaks at the retention volume of the column of 8.36 ml 
and 7.97 contained aggregated protein and DNA. ELIC and GLIC elute at 11.91 ml and at 11.75 ml, 
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respectively, which corresponds to the expected elution volume of membrane proteins with similar size 
and in the same detergent. 
 
Figure 14 Size exclusion profile of GLIC and ELIC. 
A) Size exclusion chromatogram of GLIC. Absorbance was measured at 280 nm. The peak at the retention volume 
of 11.91 ml corresponds to GLIC as confirmed by SDS-PAGE. The peak at 8.36 ml is at the void volume of the 
column. B) Size exclusion chromatogram of ELIC. Absorbance was measured at 280 nm. The peak at the retention 
volume of 11.75 ml corresponds to ELIC as confirmed by SDS PAGE. The peak at 7.97 ml elutes at the void volume 
of the column. 
 
For the selection of specific binders from libraries containing either single chain variable fragments 
(scFvs), DARPins or nanobodies, and for analysis by ELISA and surface plasmon resonance (SPR) 
GLIC and ELIC were expressed with an N-terminal biotinylation tag (Avi-tag). The lysine located within 
this 15 amino acids long tag can be biotinylated in vitro with the BirA enzyme. Biotin binds with high 
specificity and affinity to chicken avidin, the commercially available neutravidin or the fungal streptavidin. 
With this tag, the biotinylated protein can be specifically immobilized on a surface as required for various 
binding experiments. Since in this study, a N-terminal tag was used (Figure 15), in that way only the top 
of the extracellular domain of GLIC and ELIC was covered, whereas the rest of the extracellular domain 
and the membrane and the intracellular part were still accessible for binding experiments. 
 
 
Figure 15 Construct of GLIC and ELIC with an N-terminal Avi-tag. 
The construct of GLIC and ELIC (red) incorporate an N-terminal PelB signal sequence (blue), followed by a His10-
tag (light blue), MBP as fusion protein (green) and a HRV 3C cleavage site (light green). GLIC and ELIC are 
preceded by an Avi-tag (yellow) which acts as substrate for the BirA enzyme for in vitro biotinylation. 
 
As alternative to the biochemical biotinylation, a chemical modification strategy can be employed where 
a chemical reagent (EZ-Link Sulfo-NHS-LC-LC) linked to biotin, reacts with the amino group of a lysine 
on the protein surface. In this work, the biochemical biotinylation was used, because in this case the 
biotinylation site is defined and by this strategy the largest part of the protein remains accessible for 
binders. The in vitro biotinylation had no influence on the protein expression yields or function. To show 
its functionality, X.laevis oocytes were injected with mRNA coding for N-terminal Avi-tagged GLIC and 
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currents were recorded the next day by two-electrode voltage-clamp (TEVC) electrophysiology. In these 
experiments, the expression levels and functional properties of the channels can be assessed. Upon 
exposure to the agonist, protons in case of GLIC, the channel changes its conformation and ions can 
flow along their electrochemical gradient. The resulting currents can be measured and used for an 
evaluation of expression levels and functional properties. In Figure 16, the currents evoked from X.laevis 
oocytes expressing the wild type channel after exposure to high proton concentration is compared to 
those of oocytes expressing Avi-tagged GLIC. No significant difference could be observed, which 
ensures, that the addition of the tag did not alter the functional properties of the protein. 
 
Figure 16 Two-electrode voltage clamp (TEVC) of GLIC wildtype and avi-tagged GLIC 
TEVC of GLIC wild type and avi-tagged GLIC expressed on X.laevis oocytes. Currents were recorded at pH 4 and 
the voltage was clamped at -40 mV. The N-terminal Avi-tag has no influence on the protein function. The black bar 
shows currents of 4 µA. 
 
To analyze the efficiency of enzymatic biotinylation, the purified and biotinylated GLIC was mixed with 
magnetic streptavidin coated beads and, after a short incubation time, the beads binding the biotinylated 
protein were pulled down with a magnet and washed twice. The supernatant was then loaded on a SDS 
gel to evaluate the biotinylation efficiency. By that procedure it was shown that virtually all proteins bind 
to the streptavidin coated magnetic beads, thus suggesting that at least one avi-tag per pentamer is 
biotinylated (Figure 17). 
 
Figure 17 SDS-PAGE of the biotinylation test. 
Coomassie blue stained gel showing the efficiency of biotinylation. 1: Input (purified and biotinylated protein). 2: 
Supernatant after 15 min incubation with the streptavidin coated beads. 3 + 4 supernatant after 2 and 3 washing 
steps, respectively. The band between 37 kD and 25 kD correspond to the biotinylated protein. 
 
After successful purification and biotinylation of GLIC and ELIC both proteins were used for selecting 
specific protein binders with various selection methods such as Phage and Ribosome Display. 
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2.1.2 Phage Display with a single chain variable fragment (scFv) library 
Phage Display, first described in 1985 [84], is a potent method to select a specific binder for a desired 
target protein. Phages, carrying a phagemid, which is a vector containing both a phage and a bacterial 
origin of replication, display the binders as fusions to their coat proteins. Coat proteins of filamentous 
bacteriophages (e.g. M13) are genetically engineered and linked to the variable chain of an antibody 
(Figure 18). Although the genetic fusion to either the major coat protein pVIII or to the minor coat protein 
pIII is possible, the fusion to the pIII is common. 
 
 
Figure 18 Construct of a scFv linked to a phage protein. 
The genetic fusion of the heavy and the light chain to the pIII coat protein results in a phage expressing the scFv 
thereby physically connecting phenotye and genotype. For ELISA experiments a myc-tag is fused to the scFv. The 
stop codon TAG is over read by the TG1 cells, producing a scFv-protein III fusion. The coat proteins and necessary 
replication enzymes are provided by the helper phage which has a mutated origin of replication. 
 
The phages, expressing the binders as fusion proteins and thus connecting the genotype and phenotype 
of the binder in the same particle, are screened against the immobilized target protein (Figure 19). After 
incubation, unbound phages are washed away, whereas phages displaying a protein that binds 
specifically to the target are eluted and used for infecting bacteria for amplification. After superinfection 
of the bacteria with the helper phage, which supplies the viral components for ss-DNA replication and 
packaging of the phagemids into phages in the periplasms, the produced phage particles present in the 
medium are harvested and used for the next selection cycle [85]. 
 
 
Figure 19 Phage Display cycle 
A library, consisting of single chain variable fragments, displayed on the surface of phage particles is incubated with 
the immobilized target protein for binding selection. After several washing steps the specifically bound phages are 
eluted and used for infecting E.coli cells for amplification for the next selection cycle. After 3 to 4 cycles the selected 
binders are analysed by ELISA. Adapted from [86]. 
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The commonly used helper phage M13K07 has a slightly malfunctioning origin of replication and 
therefore is packaged less frequently into the phage particles. The produced phage particles incorporate 
either the scFv-pIII fusion or the pIII from the helper phage. Since most of the pIII proteins are derived 
from the helper phage and only a small fraction from the phagemid, the phages contain maximal one 
antibody fragment which is necessary for monovalent display [87, 88]. The ratios of pIII fused to a binder 
to wild type pIII can vary between 1:9 and 1:10000 [89, 90]. After 2 or 3 selection rounds the phages are 
subjected to an ELISA experiment where their binding affinity and specificity is tested. The DNA of those 
binders is sequenced and the binders are characterized by various experiments. 
Single chain variable fragments (scFv) are heterodimeric antibody fragments, which consist of the 
variable part of the heavy (VH) and the light chain (VL) of an antibody connected with a flexible polylinker 
of 15-20 amino acids (Figure 9, [91, 92]). They maintain the binding specificity and affinity of the 
conventional full length antibody [93, 94]. 
For selection of specific scFv binders for GLIC by Phage Display, the ETH-2 Gold library was used, 
which contains about 3x109  different scFv clones [95]. The library consists of the human germline heavy 
chain segment DP47 and the light chain segments DPL16 or DPK22, which represent 12%, 25% and 
16%, respectively of the antibody repertoire in humans [96]. The usage of the DP47 segment provides 
advantages as the higher thermodynamic stability [97] and the option for the purification with Protein A 
[98]. The sequence of a scFv is shown in Figure 20. 
 
 
Figure 20 ScFv sequence. 
The heavy and the light chains of the scFv are connected with a GS-linker, followed by a myc-tag, an amber stop-
codon (TAG) and the minor coat protein pIII of filamentous phage. The variable residues, depicted as X, are located 
in the complementary determining region (CDR) 3. Figure adapted from [95]. 
 
The variable residues are located in the complementary determining region (CDR) 3 which is the most 
diverse loop. The heavy and the light chain are connected with a glycine-serine linker and fused to the 
DNA of the pIII protein of the phage. This connection to the minor coat protein of filamentous phage 
ensures the physical connection of pheno- and genotype during the Phage Display selection 
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After three selection rounds a phage ELISA was performed where the total output of phages was used 
to analyze the enrichment of binders from round 1 to 3. In Figure 21 the increasing enrichment of phages 
pulled down during the selection from round 1 to 3 is visible, whereas neither cross-reactions with a 
control membrane protein nor with neutravidin or the plastic of the plate was detected. After round 3 the 
enrichment compared to background is 19-20 fold. 
 
 
Figure 21 Total phage ELISA. 
The colored bars correspond to the signals of binders of round 1 to 3. GLIC was used as target protein, as controls 
only neutravidin and a SLC11 homologue (cross-spec) were taken to determine the background of non-specifically 
bound phages. Enrichment of scFv binders for GLIC from Phage Display round 1 to 3 is clearly visible. No signals 
could be observed for wells containing either neutravidin or a different membrane protein. 
 
Subsequently, TG1 E. coli cells were infected with phages from round 2 and 3. Single colonies were 
picked and grown in 96-deep-well plates. After inoculation, a single clone ELISA of binders from round 
2 and 3 was performed to show how many specific binders were selected by Phage Display. For each 
well, a control well not containing any target protein was tested to see if the scFvs unspecifically bind to 
plastic or the coated neutravidin. These controls were used to determine the background. In Figure 22 
the ELISA signals from binders from round 2 (A) and round 3 (B) are shown. Whereas ELISA signal 
from round 2 binders are low, the signals of the round 3 ELISA are significantly over background 
(estimated as 0.05). Since either no or very low signals were observed in the control wells, were no 
membrane protein was immobilized, these scFv binders from round 3 were considered to bind 
specifically to the target protein. 
 
Figure 22 Single clone ELISA with scFv binders from round 2 and 3. 
On the Y-axis the ELISA signal is shown.Single clones are displayed in different colors. A) Single clone ELISA with 
scFv binders from round 2. All signals, except one, were low within the the background signal from wells without 
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target protein. B: Single clone ELISA with scFv binders from round 3. Many wells with signals 10 to 30 fold over 
background are observed. 
 
The scFv binders that show high and specific signals in ELISA, were sequenced. Ten different scFv 
sequences were obtained and some of them appeared more than once. The scFvs of the ETH-2 Gold 
library are composed of a heavy and a light chain (DPL16 or DPK22) and were randomized in the 
complementary determining region (CDR) 3, meaning that the differences between the individual scFvs 
consist of different light chains and different amino acids in CDR 3 [95]. In Table 1 the selected scFvs 
with their respective sequences in the CDR 3 and their frequency of appearance are listed. 
 
Name # Heavy chain DPL16 DPK22 
A 33x QTLH KPPWMP  
B 17x NSSR YDYRWP  
D 6x RSLS RPPWLP  
E 4x QTLI LPYFMP  
F 2x APWRR PVPLSS  
G 1x QSLH LPFWLP  
H 1x GTSR RWTEPP  
I 1x FTKSL HGRTPF  
K 1x NSSR KYSDLP  
C 1x SSGLS  HGLTPL 
 
Table 1 List of scFvs. 
In the first column the labels of the selected scFvs are shown. # lists the frequency of appearance of clones with 
the same sequence. E.g. scFv A was found 33 times whereas scFv K only once. The third column shows the 
sequence in the randomized CDR 3 of the heavy chain, the fourth and fifth column, the sequences of the CDR* of 
the corresponding light chains. 
 
Competent HB2151 E. coli cells were transformed with the DNA of the 10 scFvs selected by Phage 
Display and single clone ELISA. After inoculation, the cells were harvested, lysed and the scFvs were 
purified over a Protein A column, followed by a size exclusion chromatography (SEC) (Figure 23). Nine 
out of the 10 different scFvs could be successfully expressed and purified. The purity of the scFvs after 
the Protein A column purification and the size exclusion was confirmed by a SDS-Page. The two peaks 
observed after SEC (Figure 23, B) both correspond to the scFv, with the first peak potentially 
corresponding to an oligomeric state. The protein yields after SEC range between 2-10 mg/l. 
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Figure 23 Protein A column and size exclusion profile of a scFv 
A) Protein A column profile of a scFv. The blue curve shows the absorption at 280 nm. The red and the gray curve 
correspond to the conductivity and the concentration of the elution buffer, respectively. B) Size exclusion 
chromatogram of a scFv. The blue curve depicts the absorbance at 280 nm and shows a monodisperse peak. The 
retention volume of 16.52 ml corresponds to the expected molecular weight of the scFv of about 27 kDa. No 
aggregation peaks are observed. The purity of the scFvs after the Protein A column and the size exclusion was 
confirmed by SDS-PAGE and the black bar indicates the fractions that were loaded on the gel. The bands between 
25 and 37 kDa correspond to the scFv. 
 
To test if the scFv and the target protein GLIC form a stable complex, the purified scFv was mixed with 
GLIC in a 1.5 molar excess and co-migration was monitored by SEC with a Superdex S200 column. Co-
elution of both proteins means that the binders have a KD lower than 1 µM. In Figure 24 a chromatogram 
of a scFv that co-migrates with GLIC is shown. A SDS-gel of the fractions of the first peak with a retention 
volume of 10.4 ml shows both proteins, which suggests a co-migration. A peak shift towards higher 
molecular weight (from 11. 9 ml of GLIC to 10.4 ml of the complex) could be observed on SEC, which 
is due to the increased size of the complex. Due to a not strictly 1:1 binding of one scFv to one GLIC 
subunit or due to dissociation of the complex on the column, the peak is not monodisperse. The peak 
at the elution volume of 16.46 ml corresponds to unbound scFv, loaded in excess, which is confirmed 
by the SDS-gel. The small peak at 14.7 ml retention volume might contain an oligomeric species of the 
scFv. Four scFvs, named A, E, G and H co-elute with GLIC.  
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Figure 24 Size exclusion chromatogram of scFv co-eluting with GLIC 
Size exclusion chromatogram of a scFv co-eluting with GLIC. The retention volume of the first peak at 10.43 ml is 
shifted towards higher molecular weight, for about 1 ml compared to the retention volume of GLIC, indicating co-
migration of GLIC and the scFv. The peak at 16.46 ml corresponds to the unbound scFv loaded in excess. The 
SDS-PAGE confirms the co-elution of both proteins, since GLIC and the scFv are present in the first peak. The 
black bar shows the fractions selected for SDS-PAGE. 
 
To probe whether the scFvs recognize GLIC in a membrane environment and impact channel function, 
a X. laevis oocyte binding assay was performed to investigate whether scFvs would bind to GLIC 
expressed at the plasma membrane of an oocyte. The oocytes were injected with mRNA coding for 
GLIC and the protein was expressed for 2 days. Afterwards the oocytes expressing the protein and non-
injected oocytes as control, were incubated with purified myc-tagged scFvs. After 3 washing steps, 
bound scFv would be detected by an antibody binding to the fused myc-tag. No signals after adding the 
enzyme substrate could be observed, which means that the scFvs did not bind to the target protein. This 
means that the binding epitope of scFvs is not accessible to the outside either because it lies close to 
the membrane interface or on the intracellular part of GLIC. Alternatively, the vitelline layer surrounding 
the oocytes maybe impermeable for the binders. 
To obtain a general estimate of the binding affinities of selected scFvs to GLIC, the interaction was 
characterized by Surface Plasmon Resonance (SPR) spectroscopy. SPR is a useful optical method, 
which measures changes in the refractive index after binding of analytes to immobilized ligands on a 
polymer layer. This technique provides data on specificity, affinity and kinetic parameters of protein-
protein interactions [99-101]. For these investigations, purified and enzymatically biotinylated GLIC was 
coated on a ProteOn™ NLC Sensor Chip and the measurements were performed with a ProteOn 
XPR36 device. In Figure 25, SPR sensorgrams of the scFv A, E and G, applied with different 
concentrations, are shown. The data was globally fitted, using a 1:1 Langmuir kinetic model expecting 
a single scFv binding site on each subunit of the pentamer. The quality of the data and therefore its 
fitting depends on several factors such as buffer composition, purity and concentration of analyte and 
ligand, the density of immobilized membrane protein and the flow rate [102, 103]. A possible effect of 
the solvent was decreased by using the same buffer for purification of scFv and GLIC and for the 
measurement. Both proteins were subjected to size exclusion chromatography to reduce the amount of 
contaminant proteins and GLIC was biotinylated enzymatically which leads to an additional purification 
step during immobilization on the neutravidin coated chip. The immobilization density as well as the flow 
rates were adjusted according to the recommendations. The fits showed large errors potentially due to 
a possible rebinding of the analyte to the immobilized protein or due to a non-homogenous analyte. 
Despite these errors it was still possible to estimate the affinities of the present binders. Whereas the 
binding affinities of the scFv A and scFv E are in the low single-digit nano molar range, that one of the 
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scFv G is of around 50 nM. Described binding affinities of scFvs range between 10 nM up to 1 pM [104, 
105]. To determine the binding affinities with higher accuracy, additional experiments with lower analyte 
concentrations in the range of 0.1-10 times the expected KD would have to be performed [103]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25 Surface Plasmon Resonance (SPR) sensorgrams of scFvs 
Binding affinities of the scFv A (A), scFv E (B) and scFv G (C) to GLIC were analyzed with surface plasmon 
resonance (SPR). The X-axis corresponds to the time measured in seconds and the Y-axis to the response unit 
(RU). Different concentrations of analyte are used, depicted in unique colors (yellow: 600 nM, purple: 300 nM, 
green: 150 nM, dark blue) 75 nM, light blue) 37 nM, pink) 0 nM). The first dotted line shows the association signal 
of the scFvs whereas the second dotted line indicates the beginning of the dissociation. The black bar corresponds 
to 60 seconds. 
 
For co-crystallization, GLIC and the 4 single chain variable fragments that co-elute on SEC, were 
expressed and purified separately, mixed in a 1:1.5 molar ratio of membrane protein to binder. Despite 
screening in a broad range of conditions no crystals could be observed, even in conditions at low pH 
were GLIC crystallizes, indicating, that the binding of scFvs might prevent crystal formation. The co-
crystallization of the single-chain variable fragments (scFvs) together with GLIC was possibly impaired 
because the flexible GS-linker connecting the heavy and the light segment of the binding protein may 
have interfered with the formation of crystal contacts. To overcome potential problems with the flexible 
linker, the 4 scFvs A, E, G and H that co-elute with GLIC on a size exclusion chromatography were 
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converted to Fab fragments that contain the variable and one of the constant regions of the light and 
heavy chain of an antibody (see Figure 9). For that purpose, the DNA of the highly affine scFvs was 
fused to the human constant heavy and light chain on two separate vectors, which were obtained from 
CH1 of IgG1 and Cκ, respectively. After cloning of the scFvs into the corresponding vector containing 
the constant parts, the heavy and light chains were combined by vector-backbone exchange cloning 
(VBEx-cloning). The heavy and the light chain of the Fab are preceded by the signal sequences phoA 
(from alkaline phosphatase) and ompA (from outer membrane protein), respectively, which ensures the 
periplasmic expression [106]. There, the oxidizing conditions allowed the disulphide-bond formation and 
the assembly to a full-length and functional Fab.  
A Fab fragment is supposed to be less flexible than a scFv and, due to its larger size, it offers a larger 
hydrophilic surface to form new crystal contacts. Because of their larger size, Fabs could also be used 
as tools for electron microscopy to increase the size of the particle and thus facilitate its identification. 
The smallest protein thus far determined by single particle electron microscopy is the 170 kD big γ-
secretase [107], it is thus likely that a complex of Fabs binding to GLIC, with a combined size of more 
than 400 kD (assuming one Fab per subunit) should be visible in cryo EM.  
The Fab fragments, derived from the scFvs, were overexpressed in MC1061 cells and the lysate was 
purified with a Protein A column. Subsequently the Fabs were subjected to size exclusion 
chromatography. Three different Fabs (originating from scFvs E, H and G) could be expressed and 
purified. In Figure 26 an elution profile of the Protein A column purification and a size exclusion 
chromatogram is shown. On SEC, the Fab fragments elute at a volume of 16.7 ml as a monodisperse 
peak and the protein yields after purification range between 0.5-2 mg/l of expression culture. 
 
Figure 26 Protein A column and size exclusion chromatogram of Fab fragment. 
A) Protein A column chromatogram: the blue curve corresponds to the absorbance at 280 nm, the red and the green 
curve depict the conductivity and the concentration of the elution buffer respectively. B) Size exclusion 
chromatogram of a Superdex S200 column: the blue curve corresponds to the absorbance at 280 nm and shows a 
monodisperse peak of the Fab eluting at 16.7 ml. 
 
To investigate if these 3 Fab fragments still form stable complexes with GLIC, their co-migration in a 
binary complex was investigated by SEC on a preparative Superdex S200 column. In Figure 27 a 
Superdex S200 profile of GLIC co-eluting with a Fab fragment is shown. A shift in the elution volume 
towards higher molecular weight, from 11.9 ml for GLIC to 10.92 ml for GLIC in complex with the Fab 
fragment and the presence of 3 bands on SDS-PAGE (for GLIC and for the heavy and the light chain of 
the Fab) with appropriate molecular weight confirm the co-elution of the two proteins. The peak at 16.27 
ml corresponds to the unbound Fab fragments, which were loaded in excess. 
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Figure 27 Size exclusion chromatogram of a GLIC Fab complex. 
The blue curve depicts the absorption at 280 nm. The retention volume of the first peak of 10.92 ml indicates co-
migration of GLIC and the Fab fragment, since it is shifted towards higher molecular weight. The peak at 16.27 ml 
corresponds to excess unbound Fab fragments. The SDS-PAGE confirms to co-elution of both proteins, since GLIC 
and the heavy and the light chain of the Fab fragment at about 25 kD and 20 kD, respectively, are present in the 
first peak. 
To evaluate whether the binding affinities of the Fabs are similar to those of the corresponding scFv, the 
Fabs were subjected to SPR (Figure 28). The 1:1 Langmuir kinetic model, describing a single Fab 
binding on each subunit of GLIC, was used for fitting. As for the scFvs, the data only allows for an 
approximate estimate of binding affinities. It was not possible to determine the binding affinity of Fab A 
by SPR, but co-elution experiments with GLIC on SEC suggest an affinity of lower than 1µM. Fab E 
shows an estimated binding affinity in the single-digit nanomolar range which is in the same order of 
magnitude as the corresponding scFv. Fab G has a reduced binding affinity compared to the scFv G of 
about 100 nM. Fab fragment H shows similar affinities as Fab G. 
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Figure 28 SPR sensorgrams of Fab E, Fab G and Fab H 
Binding affinity of a Fab generated from scFvs binding to GLIC as measured by SPR. Runs with different Fab 
concentrations are depicted in unique colors (yellow: 600 nM, purple: 300 nM, green: 150 nM, dark blue) 75 nM, 
light blue) 37 nM, pink) 0 nM). The first dotted line shows the application of Fab and the second dotted line indicates 
the beginning of the dissociation. The black bar corresponds to 60 seconds. A) Fab E. B) Fab G. C) Fab H 
 
For co-crystallization, GLIC and the Fab fragments were expressed and purified separately, mixed in a 
1:1.5 molar ratio of membrane protein to binder and screened in a broad range of conditions. Crystals 
grew in 1 M ammonium formate, at pH 4.5, with addition of 0.05 M Na-Acetate, 10% PEG 4000, at a 
condition were GLIC crystallizes on its own. After data collection and crystallographic analysis it was 
confirmed that crystals are of the same space group as the native protein and that they only contain 
GLIC in the known conformation. 
In summary, 10 different scFvs specifically binding GLIC have been selected. Four of the selected 
binders had promising biochemical characteristics and high binding affinities and therefore could be 
purified as complex on a size exclusion column. Despite the tight binding, the co-crystallization of the 
scFv-GLIC complex was not successful. Since the GS-linker, connecting the heavy and the light chain 
of the scFvs might have prevented crystal formation, the 4 high-affinity scFv binders were converted to 
Fab fragments, which lack the flexible linker and thanks to their bigger size potentially provide additional 
surface for crystal contacts. Although the Fabs bind with similar properties as their corresponding scFv, 
no crystals of the complex were obtained. Still, the Fabs may become useful tools for single particle 
electron microscopy. As the selection of antibody-based binders from a scFv library did not allow the 
identification of novel crystal forms for GLIC, another strategy was used to obtain specific binding 
proteins with a different molecular scaffold. 
 
2.1.3 Ribosome Display with DARPins 
Designed ankyrin repeat proteins (DARPins) are synthetic proteins that were originally developed in the 
group of Prof. Dr. Andreas Plueckthun and that are based on naturally occurring ankyrins, which mediate 
protein-protein interactions in all 3 kingdoms of life [79, 80]. DARPINs are composed of multiple 
structural repeats, form elongated and slightly curved structures and therefore contain a concave binding 
surface [108]. Each repeat consists of 33 amino acids and is folded in a β-turn followed by 2 α-helices 
and a loop region. Based on their design, DARPins are composed of 2-3 internal repeats, framed by 
two capping repeats and are thus named N2C and N3C respectively. These binders have been well 
characterized. They are generally very stable due to conserved hydrogen bonds and a tight packing [78, 
109, 110]. In this study a second generation N3C-DARPin library designed by Prof. Dr. Markus Seeger 
[111] was used. In Figure 29, the general construction of such an N3C DARPin is shown with the N- 
and the C-terminal capping repeats, flanking the 3 internal repeats. 
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Figure 29 Sequence of an N3C DARPin from the new library. 
The 3 internal repeats (orange, dark and bright yellow) are flanked by an N-terminal (dark blue) and a C-terminal 
(light blue) capping repeat. Randomized positions are indicated by X. 
 
This second generation library is supposed to be more suitable for membrane proteins. It contains an 
extended randomized surface with a reduced share of hydrophobic residues and an increased fraction 
of tyrosines in the variable positions. Thanks to this design, the problems of non-specific binding of 
hydrophobic DARPins is expected to be reduced. Figure 30 compares the randomized positions in the 
internal repeat of a DARPin of the original and of the new library.  
 
 
Figure 30 Randomization of internal repeats of a DARPin of the first and second generation. 
A) Randomization of a DARPin of the original library (off7, PDP 1SVX). Seven amino acids are randomized in each 
internal repeat. B) Randomization of a DARPin of the second generation (C7_16, PDB 4JB8). The sequence and 
the color code of the diversified residues of a new library DARPin are shown at the bottom. The residues colored in 
violet D, A and S of a new library DARPin were an E, K and X in the original DARPin library. Figure adapted from 
[111]. 
 
The calculated diversity of this new library is 1.9 x 1024 [111], which is somewhat higher than  the original 
library containing 3.8 x 1023 unique proteins [109]. Due to the limitations in DNA assembly, the actual 
diversity is in the range of 1011. 
Ribosome Display is a powerful in vitro selection method for specific protein binders from large libraries. 
In this method, mRNA, coding for the DARPin binder, a T7 promoter, the ribosome binding site (RBS) 
and stem loops, is translated in vitro. A spacer sequence, lacking the stop-codon, prevents the nascent 
binder to dissociate from the ribosome and thus ensures the coupling of genotype and phenotype by 
formation of a ternary complex. The ribosomal complexes are selected from the translation mix by 
binding to the immobilized target protein. After washing away unbound complexes, the DNA encoding 
32 
 
for specifically bound proteins can be recovered and used for the next selection cycle (Figure 31). After 
3 to 4 rounds of selection, the DNA of retained binders is transformed into bacterial cells and the purified 
DARPins are analyzed by ELISA and size exclusion chromatography. The advantage of the Ribosome 
Display technique, compared to Phage Display is, that the diversity of the library is not limited by the 
transformation efficiency of bacterial cells and since with the PCR amplifications in each round, 
additional random mutations may be introduced, which could improve the binding properties further 
[112-114]. 
 
Figure 31 Ribosome Display selection cycle. 
A library consisting of mRNAs of potential binders is translated in vitro. The ternary complex, consisting of mRNA, 
the ribosome and the nascent binder is subsequently selected by binding to an immobilized target protein. After 
washing away of unbound complexes, the DNA encoding for specific binders is generated by reverse transcription, 
and amplified by PCR. Amplified DNA is subsequently in vitro transcribed and used for the next selection round. 
Figure adapted from [114]. 
 
During Ribosome Display, a critical step is the ligation of the PCR-amplified DNA segments of the affinity 
selected DARPins with the vector containing the ribosomal binding site (RBS), the T7 promoter and the 
stem loops. For that purpose, the original vector pRDV, carrying the DNA of the β-lactamase, has to be 
digested and gel-purified before it is ligated with the DNA coding for the DARPins. Despite the thorough 
digestion and purification, there was always a small fraction of non-digested vector present in the 
sample. This doesn’t cause problems as long as sufficient DARPin DNA is available and the diversity of 
the library is maintained after ligation, but in some cases this residual β-lactamase DNA can prevent 
efficient ligation and the thus reduce the diversity of the DARPin DNA pool for the next selection cycle. 
To avoid this possible problem, the selected DARPin DNA was ligated with short terminal fragments, 
containing the respective sequences required for transcription and translation of the binding proteins 
(Figure 32). Following this strategy, the ligation had to be carried out with 3 instead of 2 ligation partners 
and to make sure that the ligation efficiency was not reduced, the double amount of DNA compared to 
the original protocol, was ligated and used as template for the PCR on ligation. 
 
Figure 32 Ligation step during a Ribosome Display cycle. 
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Before transcription of the DARPin library DNA (yellow) into mRNA, a ligation step adds the T7 promoter and the 
ribosome binding site (blue) at the 5’ end, and the spacer sequence and the 3’ stabilizing stem loops (green) at the 
3’ site. Instead of ligation into the full-length pRDV vector containing these sites, ligation of only the fragments 
coding for the important sequences was carried out. 
 
2.1.3.1 DARPins selected for GLIC 
A total of four rounds of Ribosome Display with the target protein GLIC were performed with a gradual 
increase of the stringency of washing steps and a decreasing number of PCR cycles after each step. 
Since the selection was carried out at slightly basic pH, the proton-activated GLIC should be present in 
a closed, non-conducting conformation. After the fourth selection round, the DARPins were cloned into 
the arabinose-inducible pBAD expression vector, containing an N-terminal His-tag and a HRV 3C 
cleavage site. After transformation into competent E. coli MC1061 cells, a single clone ELISA with 
immobilized GLIC, detecting the His-tag of the DARPin, was performed to select for specific GLIC 
binders. Wells, only coated with neutravidin were used as control. Out of 192 tested single clones, 64 
gave a signal which was significantly higher than the background in the control wells. These clones were 
sequenced and 27 different DARPINS were found. In Figure 33 an alignment of identified binders is 
shown.  
 
Figure 33 Alignment of DARPins selected by Ribosome Display for GLIC. 
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The first sequence, named DARPin N3C, corresponds to the consensus. The X marks randomized positions in the 
library. The dots show identical residues. 
 
The selected and sequenced DARPins contain similar residues in the variable parts. Some of them only 
differ in a few amino acids and were thus predicted to bind to the same epitope (e.g DARPin G10 and 
G54 or G16 and G17). The DARPins were overexpressed in MC1061 cells and purified by Ni-NTA 
chromatography. The His-tag was subsequently cleaved with the HRV 3C protease and removed by 
binding to Ni-NTA resin and the purified DARPins were analyzed by size exclusion chromatography. For 
high-throughput screening of the DARPins, an analytical column on a HPLC system was used. Initially, 
GLIC was loaded to calibrate its elution behavior. Subsequently all the DARPins showing a 
monodisperse peak on SEC, were mixed with GLIC and loaded to investigate the migration behavior of 
the complex. In Figure 34 an overlay of size exclusion profiles of GLIC and of GLIC mixed with the 
DARPin G10 is shown. Together with the DARPin, the peak containing GLIC, shifts towards lower 
elution volumes corresponding to a higher molecular weight, strongly indicating co-migration of both 
proteins. Co-migration on SEC was also confirmed by the two bands observed on SDS-PAGE. The 
small shoulder in the SEC indicates dissociation of the two proteins during size exclusion or alternatively 
a variable binding stoichiometry of the complex. 
 
Figure 34 Overlay of elution profiles of GLIC and GLIC mixed together with DARPin G10. 
A) The blue and the orange curves depict the absorbance at 280 nm of GLIC and a GLIC-DARPIN complex 
respectively. The retention volume of the first peak of the blue curve of 0.96 ml is shifted towards higher molecular 
weight compared to the orange curve at 1.04 ml, indicating co-migration of GLIC and the DARPin. The second peak 
with a retention volume of 1.52 ml shows excess DARPin. B) SDS-PAGE confirms the co-elution of GLIC and the 
DARPin. 1: Fraction of the first peak of the blue curve showing GLIC between 37 kD and 25 kD and the co-migrated 
DARPin at 20 kD. 2: Fraction of the second peak of the blue curve showing excess DARPin at 20 kD. 
 
In Figure 35, the HPLC elution profiles of GLIC mixed with DARPins G46, G52, G54 and G57 are shown. 
In all cases a peak shift towards higher molecular weight is observed, implying co-migration of the 
complex. This expectation was confirmed by SDS-PAGE where in the first peak both proteins are 
detected. The first elution peak of GLIC mixed with the DARPin G52 (Figure 35, B) shows a shoulder 
thus suggesting the presence of a protein complex that is slightly bigger because it is shifted towards 
lower retention volume. This could be due to the binding of oligomeric DARPins to GLIC or due to further 
oligomerization of the complex. 
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Figure 35 Size exclusion profiles of GLIC DARPin complexes. 
Size exclusion profiles on an analytical column. A) GLIC co-eluting with DARPin G46 in a peak with a retention 
volume of 1 ml. The excess DARPin elutes at 1.48 ml B) GLIC co-eluting with DARPin G52 with a peak with a 
retention volume of 0.98 ml. The excess DARPin elutes at 1.5 ml. C) GLIC co-eluting with DARPin G40 with a peak 
with a retention volume of 0.99 ml. The excess DARPin elutes at 1.5 ml. D) GLIC co-eluting with DARPin G57 with 
a peak with a retention volume of 1 ml. The excess DARPin elutes at 1.54 ml. E) A SDS-gel with fractions from the 
respective HPLC runs of different GLIC and DARP complexes. The upper band between 37 kDa and 25 kDa 
corresponds to GLIC and the lower band at 20 kDa to the DARPin. 1: Fraction of the first elution peak, where co-
migration of GLIC and DARPin strongly indicates complex formation. 2: Fraction of the second peak, containing 
excess DARPin. 
 
For co-crystallisation experiments, GLIC and DARPins were expressed and purified separately. SEC-
purified and concentrated proteins were mixed in a 1:2 molar ratio and subjected to another round of 
size exclusion chromatography to confirm their co-migration. In Figure 36 a size exclusion profile of 
GLIC in complex with DARPin G18 on a preparative Superdex 200 column is shown. Two separate 
peaks correspond to the GLIC-DARPin complex and to unbound DARPin at retention volumes of 10.76 
ml and at 16.56 ml, respectively. The peak composition was confirmed by SDS-PAGE. The peak 
corresponding to the complex was collected, concentrated to 7-10 mg/ml and used for crystallization 
screening. Not all GLIC-DARPIN complexes did elute as a single monodisperse peak, which indicates 
possible dissociation or heterogeneity of the complex. This could lower the molar ratio of DARPin to 
GLIC in fractions used for crystallization screening. For this reason, for crystallization experiments, GLIC 
and DARPins were purified individually and mixed prior to crystallization in a 1:1.2 molar ratio. Although 
the DARPins are in slight molar access, a similar crystallization behavior as for the pure complex was 
expected. In complexes with DARPins G16, G18, G46 and G57 crystals could be observed in different 
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conditions at low and high pH, whereas no crystals were observed at the same conditions in controls 
only containing the respective DARPins. 
 
Figure 36 Size exclusion profile of co-migration of GLIC and DARPin G18 for crystallisation. 
Chromatogram of the GLIC–DARPin G18 complex run on a Superdex S200 column. The black bars indicate the 
fractions which were loaded for SDS-PAGE.  Two peaks with an elution volume of 10.76 ml and 16.56 ml are visible. 
The first peak corresponds to the GLIC-DARPIN G18 complex, as confirmed by SDS PAGE where a band between 
37 kD and 25 kD and a second band below 20 kD are visible. The upper band corresponds to GLIC, the lower one 
to DARPin G18. The unbound DARPin, which was loaded in excess, elutes at a volume of 16.56 ml, as confirmed 
on the SDS-gel where in fractions 19-22 only the DARPin is present. 
 
In Figure 37 selected crystals and their corresponding diffraction pattern are shown. The crystals grown 
at low pH conditions turned out to contain only GLIC. Crystals at higher pH diffracted poorly and were 
not suitable for further analysis. 
 
Figure 37 Crystals obtained for GLIC DARPin complexes. 
Top) Crystals grown in 1 M Ammonium formate, 0.05 M Na- Acetate, pH 4.5, 10 % PEG 4000, diffracted to 3.5 Å. 
Molecular replacement revealed that crystals only contained GLIC. Bottom) Crystals grown in 0.2 M Potassium 
phosphate, 0.05 M glycine pH 9.4, 10 % PEG 4000 showed poor diffraction properties. 
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Although the co-crystallization approach of the DARPins-GLIC complex has so far not allowed to obtain 
crystals of the complex at high resolution, a possible impact of the binder on the function of GLIC was 
investigated. The activation and ion conduction properties of GLIC can be investigated by two-electrode 
voltage-clamp electrophysiology with Xenopus laevis oocytes expressing the protein on the plasma 
membrane. To test if the His-tagged DARPins bind to exposed parts of GLIC on the oocyte surface and 
thus possibly alter its function, binding assays have been performed. Oocytes were injected with mRNA 
coding for GLIC and the protein was expressed for 2 days. Afterwards the oocytes expressing the protein 
and non-injected oocytes as control, were incubated with purified His-tagged DARPins and after 3 
washing steps, bound DARPins were detected with an anti-His-antibody. As for scFvs, no binding was 
detected, thus indicating that the recognized epitope may either be buried in the membrane or that the 
DARPins bind to the intracellular part of the protein. To exclude a small number of bound DARPins that 
would result in a low signal, GLIC expressing oocytes were again incubated with His-tagged DARPins 
and after 1 washing step, glutaraldehyde, a chemical crosslinking agent was added [115]. If DARPins 
were able to bind to exposed parts of GLIC they might be covalently crosslinked and it would be possible 
to preserve the complex after extraction of GLIC. Unfortunately also in this case no signal due to bound 
DARPins was observed in a Western blot, in agreement with the negative result from the oocyte surface 
ELISA. 
GLIC is activated by protons with a half maximal activation (EC50) at pH 4.8. Its structure was determined 
at low pH in a presumably conductive conformation, but Ribosome Display to select specific DARPins 
was performed at high pH where GLIC is supposed to be in a non-conductive conformation. To 
investigate whether the binding of the selected DARPins to GLIC is dependent on the pH, an ELISA 
with immobilized GLIC was performed. The incubation with the DARPins was followed by a washing 
step with buffers covering a pH range from 8 to 4.5. The bound DARPins were subsequently detected 
with a HRP-conjugated antiHis6-antibody. The results suggest a strong pH dependence of binding, since 
no signals could be detected below pH 4.75 whereas at all higher pH values all DARPins showed 
significant signals (Figure 38). Interestingly, the DARPins G16 and G20 show a maximum at pH 4.8 and 
reduced signals at pH 7 and 8, even though the selection was carried out at pH 7.5. 
 
Figure 38 pH dependent ELISA of GLIC DARPin complexes. 
After binding to the immobilized target protein, the DARPins were washed with a buffer at different pH ranging from 
4.5 to 8 and the bound DARPins detected with an antiHis6-antibody. 
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To estimate the binding kinetics of DARPins to GLIC and to classify the binders according to their affinity, 
a surface plasmon resonance (SPR) experiment was performed. For that purpose Avi-tagged and 
biotinylated GLIC was coated on a ProteOn™ NLC Sensor Chip, containing immobilized neutravidin 
and the DARPins were subsequently applied at different concentrations. The recorded data was globally 
fitted using the 1:1 Langmuir kinetic model, expecting a single DARPin binding site on each subunit. In 
all cases, the fits are poor and only allow for a semi-quantitative estimation of binding affinities. In Figure 
39 three SPR profiles are shown with DARPin G28 binding with low µM, DARPIN G52 with sub- µM and 
DARPin G18 with nM affinity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 39 SPR sensorgrams of DARPin G28, G18 and G52. 
SPR sensorgrams of three DARPins are shown. The X-axis corresponds to the time, in seconds, and the Y-axis to 
the response unit (RU). The first dotted line indicates the start of the application of the DARPins at different 
concentrations (for G28 and G18: yellow: 600 nM, pink: 300 nM, green: 150 nM, dark blue) 75 nM, light blue 37 nM, 
red) 0 nM, for G52: pink: 600 nM light blue) 300 nM dark blue) 150 nM green: 75 nM red) 37 nM orange) 0 nM) and 
was used for a fit of the association rate constant. The second line marks the beginning of DARPin washout used 
to determine the dissociation rate constant. The black bar corresponds to 60 seconds for A) and B). For C) the 
black bar corresponds to 120 seconds. A) DARPin G28. B) DARPin G18. C) DARPin G52. 
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The poor fits are potentially caused by DARPin binders, which, instead of being washed out, show 
rebinding to the immobilized ligand on the chip. This rebinding could be diminished by reducing the 
analyte concentration [103]. The DARPins G10 and G46 could not be measured by SPR, but co-elution 
experiments with GLIC on SEC suggest binding affinities below 1 µM. Reported binding affinities of 
DARPins to membrane proteins range between 9-173 nM [54], whereas for the soluble GFP, a DARPin 
with a KD of 160 pM was selected [116]. Generally, DARPins bind soluble proteins with KDs ranging 
between 4-10 nM [117]. Despite the comparably high binding affinities and the promising biochemical 
properties of selected DARPins, the original purpose of obtaining crystals of the complex in a different 
conformation diffracting to high resolution or of generating  modulators of channel function that are 
accessible from the extracellular side was not achieved. The lack of a functional phenotype could also 
be due to the hindered permeability of the binder across the extracellular vitelline layer surrounding a X. 
laevis oocyte, and binding could thus be investigated by characterizing GLIC expressed in HEK-293 
cells. 
 
2.1.3.2 DARPins selected for ELIC 
 
The structure of ELIC was determined in a supposedly closed or non-conductive conformation and so 
far no structure of ELIC in a different conformation could be obtained. In an attempt to close this gap in 
our structural understanding, three different strategies of Ribosome Display were applied to select 
binders specifically recognizing ELIC in different states. The agonist propylamine, potentially stabilizes 
an open or desensitized conformation, and the antagonist acetylcholine or the absence of any binder a 
closed conformation. A total of four rounds of Ribosome Display were performed for each condition with 
increasing stringency of the washing step and a decreasing number of PCR amplifications after each 
round of selection. After the fourth round, the DARPins were cloned into the expression vector and 
expression was carried out in E. coli MC1061 cells. Subsequently a single clone ELISA was performed 
to detect specific ELIC binders. As previously, wells coated with neutravidin were used as control. Since 
for these selections, the few obtained binders showed a certain degree of unspecific binding, the 
procedure was repeated with ELIC in the absence of any ligand. After the single clone ELISA, which 
followed the selection, the DARPins showing a significant signal over background were sequenced and 
subsequently characterized.  
In Figure 40 a sequence alignment of the selected DARPins is shown. In total 33 different sequences 
were identified for the three selections. Some sequences appeared more than once. Six DARPins did 
contain framework mutations in the third internal repeat, which contains mostly leucines and threonines. 
Also a few DARPins lacking one or more internal repeats were selected (e.g DARPin E 16). 
The selected DARPins were overexpressed in MC1061 cells and purified by Ni-NTA chromatography. 
After cleavage of the His-tag with HRV 3C protease and its removal by binding to Ni-NTA resin, the 
DARPins were subjected to size exclusion chromatography on a Superdex 200 column. In contrast to 
the DARPins selected for GLIC, the DARPins selected for ELIC showed unexpected elution behavior 
(Figure 41). Most DARPins seem to form oligomers and therefore did not elute as a single monomeric 
peak. Peaks with a low retention volume can hardly be separated from the elution peak of ELIC and it 
would thus be difficult to judge if the proteins co-migrate or if they only co-elute without binding with a 
high affinity to the channel. Consequently these oligomeric DARPins were not used for further 
investigation by surface plasmon resonance or co-crystallization. 
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Figure 40 Alignment of DARPins selected for ELIC. 
The first sequence, named DARPin N3C, corresponds to the consensus sequence. X indicates randomized 
positions in the library, the dots identical residues. 
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Figure 41 Size exclusion chromatogram of DARPins selected for ELIC. 
The blue curve shows the absorption at 280 nm. The Superdex S200 elution profiles of six selected DARPins are 
shown. A) DARPin E27, B) DARPin E28, C) DARPin E32, D) DARPin E25, E) DARPin E45, F) DARPin E47. 
 
To probe whether stable monomers can be separated from higher oligomers, the monomeric fraction of 
DARPins eluting as 2 peaks was reinjected on a SEC column.  In Figure 42, the fraction of DARPin E42 
eluting at 15 ml was reinjected on the Superdex 200 column but the resulting chromatogram again 
shows a polydisperse behavior with a second peak appearing at lower elution volume. 
 
Figure 42 Size exclusion profiles of DARPin E42 and the reinjection of fraction 9. 
A) Size exclusion profile of Darpin E42 after purification. Fraction 9 (black bar) corresponding to a monomeric 
protein was reinjected to the Superdex S200 column and again eluted as polydisperse peak with two maxima (B). 
 
Although the gel filtration profile of the two DARPins E30 and E41, show, that these binders form 
oligomers, they elute in peaks with retention volumes that could be separated from a complex peak if 
mixed with ELIC. After purification, the DARPins were mixed at a 1:1.2 molar ratio with purified ELIC 
and subjected to size exclusion chromatography (Figure 43). It appears, that the DARPin E 30 causes 
aggregation of ELIC as manifested in the large void peak in the respective chromatograms with a 
retention volume of 8 ml (Figure 43, B). The SDS-PAGE shows that ELIC is present in the first 8 
fractions, in the void peak and in the peak with a retention volume of 11.68 ml. The DARPin is partially 
eluting in the fractions of the peak at 11.68 ml and mainly in the last peak with the highest retention 
volume. Although the addition of the DARPins appears to induce aggregation of ELIC, no DARPins were 
found in the void peak. These findings suggest, that the two proteins do not co-migrate and thus the 
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DARPins have a binding affinity of lower than 1 µM. The DARPin E41 elutes in a single peak at 13.9 ml, 
which indicates a formation of oligomers (Figure 43, C). In the size exclusion profile of ELIC in complex 
with the DARPin E41 (Figure 43, D) a single peak is observed containing both proteins as confirmed by 
SDS-PAGE but, although the DARPin was loaded in excess, no peak with a retention volume 
corresponding to the size of a DARPin was detected. In this case it is possible, that this DARPin 
comigrates with ELIC, but there is also evidence, that the DARPin could be present in oligomers with 
similar retention volume and coincidentially elutes with the protein. 
 
Figure 43 Size exclusion chromatogram of ELIC mixed with DARPins. 
A, C) size exclusion chromatogram of the DARPins E30 and E41. B, D) size exclusion chromatogram of the 
DARPins mixed with ELIC. The black bar indicates the fractions that were loaded on SDS-PAGE. The bands 
between 37 kD and 25 kD correspond to ELIC whereas the bands at 20 kD correspond to the DARPins. 
 
Despite the little promising SEC data, the interaction of DARPins E30 and E41 with ELIC was 
subsequently investigated by surface plasmon resonance. The DARPins were loaded at different 
concentrations and their binding characteristics monitored. Not only in the lanes where biotinylated ELIC 
was immobilized but also in the control lanes where no protein was coated, significant signals were 
obtained. In Figure 44 the SPR sensorgrams of the DARPin E41 are shown. The signals of a control 
lane, where no protein is coated, is compared to the lane with immobilized target protein. Both 
sensorgrams are very similar and show a fast binding and very slow washout of the ligand that is 
probably due to nonspecific interactions to the matrix. Although in every cycle of the Ribosome Display 
a prepanning step was performed to dispose of unspecific, hydrophobic and neutravidin binders, such 
DARPins with this infavourable characteristic have been selected. 
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Figure 44 SPR sensorgrams of DARPin E41. 
The SPR sensorgrams of the DARPin E41 in controls (A) and in conditions containing immobilized ELIC (B) are 
shown. The first dotted line indicates the loading of the DARPin at different concentrations (shown in unique colours, 
yellow) 600 nM, pink) 300 nM, green) 150 nM, dark blue) 75 nM, light blue 37 nM, red) 0 nM). The second line 
marks the start of the wash-out. The black bar corresponds to 120 seconds.  
 
In summary, several DARPins targeting ELIC have been selected by Ribosome Display. Although a 
DARPin library of the second generation was used, which was specially designed for membrane proteins 
[111], all of the selected DARPins show unfavorable biochemical characteristics such as oligomerization 
and the formation of soluble aggregates. Interestingly this behavior was not observed in the selection of 
the related channel GLIC. Since these DARPins cannot be used for a structural or functional 
investigations of ELIC, a different strategy to select other binders was followed. In the next chapter the 
selection of nanobodies targeting ELIC is described. For that purpose, Alpacas were immunized with 
the target protein and the DNA of the variable part of their heavy chain antibodies was cloned into a 
library. Subsequently, Phage Display with this targeted nanobody library was performed to identify 
promising binders. 
 
2.1.4 Alpaca Immunization and Nanobody selection by Phage Display 
To produce nanobodies that specifically bind to the respective targets, alpacas were immunized with 
freshly purified ELIC. After 4 injections every two weeks, the B-lymphocytes containing the mRNAs of 
the entire population of immunoglobulins including conventional and heavy chain only antibodies, were 
collected from the blood. After reverse transcription, the DNA encoding for nanobodies, was cloned into 
a Phage Display library, which was subsequently used for 2 cycles of Phage Display with Avi-tagged 
detergent purified target protein. During the second selection round, the stringency of the washing was 
increased and afterwards a total phage ELISA was performed to monitor the enrichment of binders 
during the two rounds of selection compared to the initial library. 
After the Alpaca immunization and the subsequent Phage Display, a total phage ELISA was performed 
to determine the enrichment of binders during the two rounds, compared to the library constructed after 
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the immunization. In Figure 45 a 10-fold enrichment compared to round zero (which corresponds to the 
library or the input phages) and round 2 can be observed. No big signal with round 2 phages was 
detected with the negative control, consisting of other membrane proteins, injected in the same animal. 
 
Figure 45 Total phage ELISA with nanobodies selected for ELIC. 
Compared to round 0 (library, input phages) and round 1 a ten-fold enrichment of the signal after round 2 can be 
observed (blue bars). Round 2 phages showed no signal to other membrane proteins (red and orange bar), which 
were injected into the same animal. 
 
E. coli cells were subsequently infected with round 2 phages and a single clone ELISA was performed. 
The nanobodies providing a significant signal were sequenced and subsequently analysed. In Figure 
46 an alignment of sequences of the nanobodies is shown. Remarkably, the differences appear not only 
in the complementary determining regions (CDRs), as expected, but also in the framework. 
 
Figure 46 Alignment of nanobodies selected for ELIC. 
Identical residues are depicted as dots. The complementary determining regions (CDRs) are indicated by the black 
bars. Besides variations in the CDRs there are also mutations in the framework of the nanobodies. 
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The nanobodies coding for these sequences were subsequently cloned into the expression vector, 
carrying an N-terminal PelB signal sequence, a His-tag, MBP and the HRV 3C cleavage site, and the 
protein was expressed and purified. After affinity purification on Ni-NTA resin, cleavage of the His-tagged 
MBP with HRV 3C protease and a second Ni-NTA column purification step the nanobodies were 
analyzed by size exclusion chromatography. All selected nanobodies elute as a single monodisperse 
peak. Purified nanobodies were mixed with purified ELIC and the co-migration of both proteins was 
investigated by SEC. Peak fractions were collected and analyzed by SDS- PAGE. In Figure 47 the size 
exclusion chromatograms of ELIC with the nanobodies 8, 9, 4, 16.1 and 16.2 and a SDS- gel with the 
corresponding peak fractions are shown. It is apparent, that the nanobodies 8, 9, and 16.2 co-elute with 
ELIC, as manifested by the 2 bands on the SDS- gel, whereas the nanobodies 4 and 16.1 do not co-
migrate, since only ELIC was detected in a collected fraction of the first peak. Following this initial 
characterization, the preparations of ELIC-nanobody complexes were scaled-up and subjected to broad 
crystallization screening. Despite the promising biochemical behavior no crystals were identified for any 
of the three complexes. 
 
Figure 47 HPLC chromatogram of nanobodies and ELIC 
A-E) Examples of nanobodies tested for co-migration with ELIC. ELIC in complex with A) nanobody 8, B) nanobody 
9, C) nanobody 4, D) nanobody 16.1, E) nanobody 16.2. SDS-PAGE of the first peak. A band running between 37 
kD and 25 kD corresponds to ELIC (see also the last lane on the gel that only contains ELIC), and a band between 
10-15 kD to the nanobody. 
 
The purified nanobodies were subjected to surface plasmon resonance (SPR) to evaluate the binding 
kinetics and to classify the nanobodies according to their affinities to ELIC. Avi-tagged and biotinylated 
ELIC was coated on a ProteOn™ NLC Sensor Chip and the nanobodies were applied in different 
concentrations (Figure 48). From the association and the dissociation properties, the binding affinity can 
be calculated. The data was fitted, using the 1:1 Langmuir kinetic model, expecting one nanobody 
binding site per subunit. Nanobody 1 has an estimated binding affinity of more than 1 µM, which is 
supposed to be the limit for co-migration on a SEC column (Figure 48, A). Nanobodies 8 and 9 show 
binding affinities of about 80 and 100 pM, respectively (Figure 48, B and C). 
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Figure 48 SPR sensorgrams of the nanobodies 1, 8 and 9. 
SPR sensorgrams of 3 nanobodies (nbe 1, 8 and 9) are shown. The X-axis corresponds to the time, measured in 
seconds and the Y-axis to the response unit (RU). The first dotted line indicates the loading of the DARPin at 
different concentrations (shown in unique colors: yellow, 900 nM, pink, 450 nM, green, 225 nM, dark blue, 112 nM, 
light blue, 56 nM, red, 0 nM). The second line marks the start of the wash-out. The black bar corresponds to 120 
seconds. A) SPR sensorgram of nanobody 1. B) SPR sensorgram of nanobody 8, C) SPR sensorgram of nanobody 
9. 
 
The relatively poor fit of the SPR sensorgrams of the nanobodies 8 and 9 could be due to non-specific 
binding. Similarly to the DARPins selected for ELIC, the nanobodies showed a high degree of unspecific 
binding as indicated in Figure 49. When comparing the signals of the control lanes, where no protein 
was coated, with those were the biotinylated target protein ELIC was immobilized, a similar behavior 
was detected. It appears, that the nanobody interacts with the surface of the chip consisting of 
neutravidin and alginate (www.biorad.com). Neutravidin was present during Phage Display which could 
have led to the selection of neutravidin-binding nanobodies, although a prepanning step was always 
performed to prevent this. 
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Figure 49 SPR sensorgram of nanobody 4 
SPR sensorgram of nanobody 4. The first dotted line indicates the loading of the DARPin at different concentrations 
(shown in unique colors: yellow, 900 nM, pink, 450 nM, green, 225 nM, dark blue, 112 nM, light blue, 56 nM, red: 0 
nM). The second line marks the start of the wash-out. The black bar corresponds to 120 seconds. A) Signal of 
nanobody 4 in control lane where no protein was immobilized. B) Signal of nanobody 4 in lane with immobilized 
target protein ELIC. 
 
With the attempts to generate binders to ELIC, twelve nanobodies were identified which specifically 
recognize the membrane protein, following the immunization of Alpacas and the subsequent selection 
by phage display. Nine of these binders could be expressed and purified and show promising 
biochemical characteristics. Four of them bind ELIC with affinities below 1 µM and thus co-migration on 
a size exclusion chromatography. Although no crystals of the complex with ELIC were obtained, the 
nanobodies could potentially be used for future experiments investigating a possible impact on the 
function of the channel. For this purpose binding of YFP-fused nanobodies could be generated to detect 
binding in HEK-293 cells expressing the channel. Binding to an intracellular epitope could be detected 
by co-expression of ELIC with the nanobody, binding to an extracellular epitope by addition to the 
outside. A functional effect could be investigated by patch-clamp electrophysiology in the inside-out or 
outside-out configuration. 
 
2.1.5 Summary 
In the previous chapters the attempts to generate binders to the prokaryotic pLGICs ELIC and GLIC 
from three different structural frameworks have been described. These attempts allowed the successful 
selection of 10 different single-chain variable fragments (scFvs) and 27 different designed ankyrin repeat 
proteins (DARPins) recognizing GLIC by Phage and Ribosome display, respectively. Binding was 
confirmed by ELISA, size exclusion chromatography, surface plasmon resonance (SPR), and 
complexes were used for crystallization screening. Four out of the 10 selected scFvs showed a binding 
affinity (KD) lower than 1 µM and thus co-migrated as complex with GLIC on size exclusion 
48 
 
chromatography. Since the pentameric GLIC (185 kD plus the detergent micelle) is much bigger than 
the monomeric scFv (25 kD), the complex can be efficiently separated from the unbound binder. If the 
scFv binds to GLIC with a low enough KD, the resulting protein complex is bigger than GLIC and a shift 
in the elution volume can be observed, which indeed the case was. Co-elution was confirmed by SDS-
PAGE, where the target protein and the binder are both present in the corresponding elution peak. 
Despite broad screening it was not possible to co-crystallize any scFv-GLIC complex. Since in these 
cases not even crystals of the isolated membrane protein were observed, the complex may have stayed 
intact even at low pH where GLIC readily crystallizes. The scFvs have a 14 amino acid long linker, 
connecting the two variable parts, which might prevent effective crystal formation. To avoid this flexibility, 
the 4 scFvs that bind with a high affinity to GLIC, were cloned into Fab fragments in order to obtain a 
more stable molecule for crystallization. Similar binding affinities to the target protein were confirmed by 
size exclusion chromatography and SPR. Although no crystals were observed in co-crystallization 
assays either, these larger Fab fragments binding to GLIC can potentially be used as tools for single 
particle electron microscopy. 
Specific protein binders can also have an impact on the function of the targeted protein [53-55], by either 
occupying an agonist binding site or preventing conformational changes. However, no binding of the 
scFvs to GLIC expressed on X. laevis oocytes could be detected, indicating that the epitope is not 
accessible to the outside, and thus no functional experiments could be performed. 
The 27 DARPins, selected against GLIC by Ribosome Display from a DARPin library of the second 
generation [111], were characterized with respect to their binding properties. A subset of eight DARPins 
showed high binding affinities in the nanomolar range. With some DARPin-GLIC complexes it was 
possible to obtain crystals at neutral and high pH, all of them diffracted poorly as it is the case with 
crystals with GLIC alone grown at high pH. 
To probe a potential impact of the selected DARPins on protein function, it was investigated whether 
these highly affine binders were are able to bind to GLIC expressed on the X.laevis oocytes. Since, 
similarly to the experiment with the scFvs, no binding was detected, it thus appears that the epitope is 
not accessible from the outside of the oocyte and it may instead either be buried in the membrane or 
located at the intracellular side. 
Different to GLIC, the DARPins selected for ELIC all showed the formation of oligomers or soluble 
aggregates, which is common for membrane protein binders [54, 57, 81]. By using a DARPin library of 
the second generation [111] the amount of such binders ideally should be reduced. Because of these 
unfavorable biochemical properties, only 2 DARPins were subjected to surface plasmon resonance to 
quantify their binding behavior. As expected, they both bind unspecifically also to lanes were no target 
protein was immobilized. Nanobodies selected by immunization of Alpacas followed by 2 rounds of 
phage display, show favorable biochemical characteristics and have high binding affinities, but some of 
them also show some degree of unspecificity during surface plasmon resonance (SPR), similar to the 
DARPins for ELIC.  Since after the immunization of the alpaca, 2 rounds of Phage Display with the target 
protein immobilized via neutravidin were performed, it is possible that some nanobodies were selected 
which bind to neutravidin despite the prepanning step that should remove such binders from the pool. 
Since the binder approach to determine the structure of the two target proteins ELIC and GLIC in a 
different conformation was unsuccessful, a different strategy to characterize the gating mechanism of 
pLGICs was followed. The binding site of the agonist is located between two subunits at the extracellular 
domain. After binding, a conformational change has to be transduced over a long distance to the 
transmembrane part where the pore opens. The interface between the extracellular and the intracellular 
domains of the proteins is therefore supposed to play an important role in signal transduction. In the 
following section, the impact of mutations of residues located in this interface region are presented. 
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2.2 Functional characterization of GLIC and ELIC 
The functional properties of the pentameric ligand gated ion channels GLIC and ELIC expressed in 
X.laevis oocytes can be characterized by two-electrode voltage clamp (TEVC) electrophysiology. With 
this technique changes in ion conduction following the application of agonist can be recorded. During 
this process, a conformational change of the channel is triggered by agonist binding in the extracellular 
part to a site located between two subunits. This binding leads to a conformational rearrangement in the 
transmembrane domain resulting in channel opening by a so far unknown allosteric process. In 2004, 
Bouzat and colleagues identified regions in the interface between the extracellular and transmembrane 
domains which play an important role in channel gating. Chimeras of the acetylcholine binding protein 
(AChBP) and the pore domain of the serotonin receptor only showed activation, when the β1-β2 loop, 
the β6-β7 loop and the β8-β9 loop, located at the extracellular part, were exchanged with the 
corresponding loops of the homologue forming the pore. This underlines the importance of the coupling 
of these loops with the α2-α3 loop from the transmembrane part for function [44]. Previously, several 
amino acids located in these loops and in close proximity in the interface were mutated to alanine and 
the effect on function was analyzed. (Figure 51, see also Ph.D. thesis of Carlo Bertozzi, UZH 2014). As 
part of the work of this thesis, several residues were analyzed more thoroughly and the combined data 
was described in a publication (see publication “Signal transduction at the domain interface of 
prokaryotic pentameric ligand-gated ion channels” in the Appendix). 
 
 
 
Figure 50 Domain interface of GLIC and ELIC. 
A) Sequence alignment of GLIC and ELIC. Mutated residues are colored in red. Identical residues in blue. 
Secondary structure elements and residue numbering are shown. The yellow boxes highlight the residues that were 
characterized and described in the publication in the Appendix. B) Cartoon representation of a monomeric subunit 
of GLIC and ELIC. The residues mutated in the domain interface of GLIC (green) and ELIC (cyan) are shown as 
spheres. The figure was created with Pymol. 
 
In a set of experiments the maximum response of the protein at high agonist concentration was 
correlated with the expression level at the plasma membrane. The correlation between currents and 
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surface expression was investigated in a semi-quantitative manner and mutants were identified that do 
no longer respond to agonist despite their correct folding and targeting to the plasma membrane. For 
functional analysis by two-electrode voltage-clamp (TEVC) electrophysiology, the mRNA coding for 
GLIC and ELIC fused to an N-terminal hemagglutinin-tag, was injected into defolliculated oocytes. The 
time dependence of expression of the correctly folded channels was investigated with an oocyte surface 
assay where the hemagglutinin-tag was detected by an antibody after 1, 2 and 3 days of injection of the 
mRNA coding for the corresponding protein. For WT and for most of the mutants analyzed in this study, 
highest expression levels were observed 2 days after injection. All subsequent experiments, such as 
two electrode voltage clamp recordings to measure the evoked currents upon ligand exposure, and 
oocyte surface assays were thus performed at this stage. To investigate the correlation between 
expression of the channels and activity measured by TEVC, for each oocyte the amount of expressed 
proteins detected by a surface assay was related to the maximal current evoked after application of the 
agonist (Figure 51). The more protein is expressed on the oocyte, the higher the maximal current should 
be. Supposing all proteins on the surface are functional and activated by the applied ligand and all the 
fused hemagglutinin-tags are bound by the antibody, a linear dependence of expression and current 
response can be expected. In Figure 51, TEVC electrophysiology measurements of the wild type 
proteins, subtracted by the background signal of non-injected cells, are shown. For oocytes expressing 
wild type GLIC, a weak correlation between the signal observed in the oocyte expression test and the 
maximal current response can be observed, at least for low to medium expression levels (Figure 51, A). 
For oocytes expressing ELIC, a similar weak correlation was observed (Figure 51, B). However, the 
scattering of data points in both cases is quite large, which could be due to proteins that conduct ions 
but, for sterical reasons do not bind to the hemagglutinin-antibody, or which could also reflect different 
levels of desensitized proteins. 
 
 
Figure 51 Correlation of maximal current and expression in oocytes. 
The expression of GLIC and ELIC wild type in X.laevis oocytes was quantitated by a surface assay detecting the 
fused hemagglutinin tag. The maximal current (in µA) of each oocyte was measured by two electrode voltage clamp 
electrophysiology and correlated to the amount of expression (luminescence). A) Maximal currents versus 
expression of GLIC WT in oocytes. B) Maximal currents versus expression of ELIC WT in oocytes. 
 
2.2.1 The β6–β7 and the α2-α3 loop 
The β6–β7 loop from the extracellular domain of the protein (termed cys-loop in eukaryotes) is highly 
conserved within the family and was shown to play an important role in channel gating of glycine 
receptors [118]. In this study, two residues of this loop, were identified whose mutation to alanine had a 
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severe impact on channel activation in both homologues, GLIC and ELIC. In Figure 52, the residues 
which were mutated are shown as spheres in a cartoon representation. 
 
Figure 52 The β6–β7 loop of GLIC and ELIC. 
Cartoon representation of the phenylalanine and aspartate in the β6–β7 loop of GLIC (green) and ELIC (cyan). The 
Figure was created with Pymol. 
 
In GLIC the mutation of aspartate at the position 121 and the phenylalanine at the position 115 resulted 
in loss of function phenotypes, as characterized by TEVC electrophysiology were the evoked currents 
are compared with those of the wild type channel and those of non-injected oocytes (Figure 53, A). To 
make sure that the channels are folded correctly and expressed on the plasma membrane of the oocyte, 
a surface assay was performed, where a hemagglutinin tag was detected, and the expression levels 
were compared to WT (Figure 53, C). The mutant Phe115 showed robust expression which means that 
the channel is correctly folded and transported to the plasma membrane of the oocyte, whereas the 
D121A mutation has led to a slightly reduced expression level. Both Phe115 and Asp121 are important 
for channel gating as indicated by the lack of currents in TEVC electrophysiology. In ELIC, the F116A 
mutant was expressed to a similar extend on X. laevis oocytes than the corresponding wild type 
measured by an oocyte surface assay. Similarly to GLIC, the D122A mutant of ELIC showed reduced 
expression levels. Upon application of the agonist, no current was evoked by either mutant (Figure 53, 
B and D) thus underlining a similar importance of these residues for channel gating also for this 
homologue. 
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Figure 53 Maximal currents and expression of GLIC and ELIC mutants. 
A) Maximal current of representative X.laevis oocytes expressing GLIC wild type, and mutants F115A and D121A 
compared to non-injected oocytes. Currents were measured at pH 4 and the voltage was clamped at -40 mV. B) 
Maximal current of X.laevis oocytes expressing ELIC wild type, and mutants F116A and D122A compared to non-
injected oocytes. Currents were measured in response to application of 25 mM cysteamine and the voltage was 
clamped at -40 mV. C) Oocytes surface expression of the 2 mutants compared to the wild type GLIC and non-
injected oocytes. D) Oocyte surface expression of the two mutants compared to ELIC wild type and non-injected 
oocytes. For each construct, at least 10 oocytes were measured and normalized to wild type, the errors are standard 
errors of the mean (SEM). 
 
The β6–β7 loop (cys-loop) of the extracellular domain interacts with the α2-α3 loop of the 
transmembrane domain. To investigate the influence of single residues located in the α2-α3 loop on 
channel gating, they were mutated to alanine and analyzed by two-electrode voltage clamp 
electrophysiology. X. laevis oocytes expressing the mutations L245A, T248A, Y250A of GLIC and 
L253A, L256A, Y258A of ELIC, did not show any current response after application of the corresponding 
agonists at high concentrations, indicating that they are indispensable for channel function. To ensure 
that the mutations did not lead to a misfolded channel that would not be transported to the plasma 
membrane of the oocyte, a surface assay was performed to quantify the expression levels and compare 
them to the corresponding wild type protein, which was measured in the same experiment with the same 
batch of oocytes. The GLIC mutants all show robust expression, the threonine mutant (T248A) even 
expresses twice as much as GLIC WT (Figure 54, A). A similar behavior is observed for corresponding 
ELIC mutants where the leucines Leu253 and Leu 256 express similar or even better than WT. Only the 
Y258A mutant shows slightly reduced signals during the surface assay, but is still significantly higher 
than non-injected oocytes (Figure 54, B). 
 
Figure 54 Expression of mutants in the α2-α3 loop of GLIC and ELIC. 
A) Expression of 3 GLIC mutants in X. laevis oocytes compared to the wild type. All mutants show robust expression 
levels. B) Expression of 3 mutants of ELIC expressed in X. laevis oocytes compared to the wild type. Whereas the 
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mutants L253A and L256A expressed robustly, the mutant Y258A only shows 30% of the wild type signal. Data 
show the mean of at least 10 oocytes and are normalized to wild type. The errors are SEM. 
 
2.3.2 Salt bridge 
The β1–β2 turn of the extracellular domain of GLIC is stabilized by a conserved salt-bridge between an 
aspartate (Asp31) from the β1–β2 turn and an arginine (Arg191) of the β10-α1 linker (Figure 55). In 
ELIC this salt-bridge is absent and the conserved negatively charged residue, which forms this 
interaction in GLIC, is a polar threonine at position 28. In the structure of the non-conducting 
conformation of ELIC there is no contact between the conserved Arg199 and Thr28 (Figure 55). The 
salt bridge observed in GLIC is supposed to play an important role in channel gating in the nAChR and 
its formation was proposed to be the key event for channel opening [42, 119]. 
 
 
Figure 55 Salt bridge in the interface of GLIC and ELIC. 
Cartoon representation of the salt bridge in the domain interface of GLIC (green) and ELIC (cyan). In GLIC Arg191 
and Asp31 are forming a salt bridge. This connection is disrupted in ELIC, where the equivalent position in the β1-
β2 turn contains a threonine (Thr28). The Figure was created with Pymol. 
 
The mutation of the residues in the β1-β2 loop (Asp31) and in the β10-α1 linker (Arg191) of GLIC to 
alanine caused a lack of response in TEVC electrophysiology measurements (Figure 56, A). The 
mutation of the corresponding residue in the β10-α1 linker (Arg199) in ELIC also shows a similar loss of 
function phenotype. However, unlike in GLIC, the ELIC mutation T28A, located in the β1-β2 loop, shows 
low currents upon application of the agonist, which indicates that this position might be less critical in 
ELIC for channel opening than in GLIC (Figure 56, B). To prove, that the channels are correctly folded 
and expressed on the X. laevis oocyte membrane, a surface expression assay was performed where a 
hemagglutinin-tag fused to the channels was detected by an antibody. When comparing the signals of 
the mutated GLIC channel to the wild type protein and to non-injected oocytes, it is apparent, that the 
mutation of the Arg191 resulted in a defective channel, which is not expressed on the plasma 
membrane, whereas the D31A mutant shows comparable expression levels as the wild type channel 
(Figure 56, C). In ELIC, the mutant channels T28A and R199A show reduced expression on the X. laevis 
membranes compared to the wild type protein, thus suggesting a potential impact of the mutation on 
folding (Figure 56, D). The correlation of expression and maximum current of the threonine mutant T28A 
will be discussed later. 
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Figure 56 Maximal currents and expression of the residues involved in a salt bridge in GLIC and ELIC. 
A) Maximum current response of X. laevis oocytes expressing GLIC wild type and the Asp31 and Arg191 mutant 
compared to non-injected oocytes. Currents were measured at pH 4 and the voltage was clamped at -40 mV. B) 
Maximum current response of X. laevis oocytes expressing ELIC wild type and the Thr28 and Arg199 mutant 
compared to non-injected oocytes. Currents were measured in response to addition of 25 mM cysteamine and the 
voltage clamped at -40 mV. C) Surface expression of the mutants D31A and R191A in X. laevis oocytes compared 
to wild type GLIC. D) Surface expression of the mutants T28A and R199A in X. laevis oocytes compared to wild 
type ELIC. Data show averages of at least 9 oocytes and are normalized to wild type, errors are SEM. 
 
In acetylcholine receptors it was found, that single mutations of the residues participating in a salt bridge 
between the corresponding sites, which reverses their charge, resulted in reduced gating equilibrium 
constants, whereas the combination of these mutations show wild type like behavior [21, 23, 120]. To 
investigate the impact of a similar mutation, in both homologues, GLIC and ELIC, a ‘charge reversal’ 
mutation of the salt bridge was constructed, where the positions of the involved amino acids in ELIC 
and GLIC were switched. The switch of Arg191 and Asp31 in GLIC has a severe impact on function 
while its expression in X. laevis oocytes is not affected. Despite the high expression level on oocytes 
surfaces compared to wild type GLIC (Figure 57, B), only currents similar to those of non-injected 
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oocytes in response to application of a buffer with low pH could be detected, suggesting that the mutation 
leads to a complete loss of activation (Figure 57, A). 
 
Figure 57 Two-electrode voltage clamp measurements and surface expression of X. laevis oocytes 
expressing GLIC wild type protein and the “charge-reversal“ mutant. 
A) Maximum current response at pH 4 with non-injected X. laevis oocytes, GLIC wild type and the charge-reversal 
mutant of GLIC. The black bar indicates a current of 2 µA. B) Expression of GLIC wild type and the mutant 
D31R_R191D on the surface of X. laevis oocytes compared to non-injected oocytes. Data show averages of at 
least 10 oocytes and are normalized to wild type, errors are SEM. 
 
To investigate the potential structural rearrangements underlying the loss-of function of the charge-
reversal mutant of GLIC, both mutated homologues (GLIC and ELIC) were overexpressed in E.coli cells 
following the same protocols as for the respective wild type proteins. After expression, the cells were 
harvested, lysed and the protein was extracted with detergents. Subsequently, the solubilized mutant 
proteins were purified by immobilized metal affinity chromatography (IMAC). After incubation with the 
HRV 3C protease to cleave the fusion protein, and dialysis into imidazole-free medium, the His-MBP 
fusion was separated from the channel by a second IMAC step. The concentrated flow-through fraction 
containing the channel proteins were run on SEC. During this purification the pentameric GLIC mutant 
with an elution volume of 11.7 ml could be successfully separated from the aggregation peak (Figure 
58, A) whereas the corresponding mutant of ELIC was completely aggregated (Figure 58, B), as 
indicated by the large peak with the retention volume around 8 ml, which corresponds to the void volume 
of the column. 
 
Figure 58 Size exclusion profiles of the charge reversal mutations of GLIC and ELIC. 
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Absorbance was measured at 280 nm. The black bars show the fractions which were loaded on the SDS-gel. A) 
Size exclusion chromatogram of GLIC D31R_R191D. The peak at the retention volume of 11.73 ml corresponds to 
the protein, as confirmed by SDS-PAGE. The peak at 8.16 ml corresponds to the void volume of the column. B) 
Size exclusion chromatogram of ELIC T28R_R199D. The protein appears to be aggregated, since only one peak 
at the void volume of 8.06 ml is observed. 
 
After size exclusion chromatography, the fractions containing the “charge-reversal” mutant of GLIC were 
collected and concentrated up to 7.5 mg/ml and subjected to broad crystallization screening. The mutant 
was successfully crystallized in the known crystallization conditions of GLIC (225 mM (NH4)2SO4, 50 mM 
sodium acetate, pH 4.0 and 4.5, 9–12% PEG 4000 and 0.5 mg/ml E. coli lipids). Crystals were harvested 
and cryo-protected by soaking in mother liquor containing additional 30% ethylene glycol and data was 
collected at the Swiss Light Source of the Paul Scherrer Institute. The crystal structure of the double 
mutant was determined at 3.2 Å. Although the molecule in most parts shows comparably small 
differences compared to wild type GLIC, the exchange of the two amino acids, causes a large 
conformational change at a site distant form the mutation. In the pore lining α-helix 2 significant 
differences are observed. In Figure 59, the superimposition of the charge reversal mutant and GLIC wild 
type shows the tilt of α-helix 2 with respect to the orientation in the WT. 
The C-terminal part of this helix (Figure 60 B, blue) is tilted towards the pore and appears to close it, 
which might be the cause of the loss of ion conduction. Interestingly the electron density at the mutated 
region shows that the residues that have been exchanged in the mutant, may be involved in similar 
interactions as found in wild type (Figure 60). 
 
Figure 59 Superimposition of charge reversal mutant and GLIC wild type. 
Superimposition of one subunit of GLIC (green) and the charge reversal mutant (blue) in two different orientations. 
The mutated residues are shown as spheres. The Figure was created with Pymol. 
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Figure 60 Electron density and statistics of the charge reversal mutation of GLIC. 
Electron density of the charge reversal mutant of GLIC where the positions of residues Asp31 and R191 involved 
in a salt bridge have been exchanged. A) Superimposition of one subunit of GLIC wild type (green) and the charge 
reversal mutant (blue). 2Fo-Fc electron density of the charge reversal mutant (calculated at 3.1 Å and contoured at 
1σ) superimposed on the structure α2 helices of the mutant (blue) and wild type GLIC (green). B) The residues of 
GLIC wild type (green) and the charge reversal mutant (blue) are depicted, indicating a potential interaction that 
has been observed in WT. C) Data collection and refinement statistics of the GLIC charge reversal mutant. 
 
As shown before, the mutation of Asp 31 to alanine prevents channel activation of GLIC (Figure 56, A). 
In contrast, the mutation of the equivalent position in ELIC (T28A) can still be activated but shows lower 
maximal currents. In Figure 61, maximal currents of the mutant T28A and T28D, where a residue is 
introduced that is present in other family members (such as GLIC), are shown in comparison to non-
injected and oocytes expressing ELIC wild type. All measurements were performed with the same batch 
of oocytes and expression was quantified in the same round of experiments. Compared to ELIC WT, 
both the alanine and the aspartate mutants show lower maximal current response. These findings 
support the assumption, that also the threonine at this position is important for function but that the 
impacts on function of mutations are not as severe as observed for the equivalent position in GLIC. 
Interestingly the reduced currents, resulting from the introduction of a possible partner for a salt bridge 
with the arginine from the β10-α1 suggest that the mutation might have either decreased the expression 
level, the single channel conductance or the maximum open probability of the channel. 
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Figure 61 Maximal currents of ELIC mutants in the β1- β2 turn. 
Maximum currents of X. laevis oocytes injected with ELIC and the two Thr28 mutants in comparison with non-
injected oocytes. Currents were measured at 25 mM cysteamine and the voltage clamped at -40 mV. The black bar 
shows currents of 5 µA. 
 
To investigate the density of proteins on the surface of X. laevis oocytes, the expression levels of ELIC 
WT and the two mutants of Thr28 were quantified (Figure 62, A). The T28D mutant has a comparable 
expression level to the wild type protein, whereas the T28A mutant expresses at lower levels. As shown 
above, both mutants can still be activated by the agonist cysteamine. Since in case of T28A, fewer 
mutant channels are expressed on the oocyte surface, the maximum currents are consequently 
reduced. To further relate the expression levels to the evoked maximum currents the ratio of both signals 
was evaluated and compared to WT. For both mutants the ratio of activity to the expression level is 
much lower than in case wild type ELIC (Figure 62, B) indicating that the presence of the threonine is 
important for channel function and that the substitution to either alanine or an aspartate (the residue that 
is present in GLIC) may either decrease the single channel conductance or the maximum open 
probability of the channel. Since the single channel conductance of T28D is unaltered (see publication 
“Signal transduction at the domain interface of prokaryotic pentameric ligand-gated ion channels” in the 
Appendix), it is likely that the maximum open probability is reduced. 
 
Figure 62 Expression and Imax/Expression of ELIC wild type and Thr28 mutants. 
A) Expression of ELIC wild type, and the mutants T28A and T28D on X. laevis oocytes, compared to non-injected 
oocytes. B) Ratio of the evoked current to the expression level. At least 10 oocytes were measured and are 
normalized to wild type. Errors are SEM. 
 
To quantify the correlation between expression of the channels and activity measured by TEVC 
electrophysiology in single cells, for each oocyte the amount of expressed proteins, detected by a 
surface assay, was related to the maximal current evoked after application of the agonist (Figure 63). 
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The two mutants show a different correlation of expression and activity compared to the wild type protein 
(Figure 63, A). Although the amount of expression of the T28D mutant is comparable to wild type, as 
indicated by the similar distribution of the luminescence signal, the evoked maximal currents after 
agonist application are significantly reduced. In contrast, the alanine mutant is poorly expressed and 
consequently shows very low currents, in line with the analysis of the average current density shown 
above (Figure 63, B). Taken together, this findings emphasize the importance of the threonine at this 
position for channel activation in ELIC. 
 
Figure 63 Correlation of maximal current and expression. 
The expression of ELIC wild type and mutants of Thr 28 in X. laevis oocytes was quantitated by a surface assay 
detecting the fused hemagglutinin tag. The maximal current of each oocyte was measured by two electrode voltage 
clamp (µA) and correlated to the amount of expression (luminescence). A) Non-injected oocytes (blue) were 
compared to oocytes expressing the wild type channel (orange), the T28A mutant (grey) and the T28D mutant 
(yellow). B) Same representation with magnified y-axis and wild type ELIC data omitted. 
 
Although both mutants appear to have a similar maximum open probability, the potency of agonist is 
highly enhanced in T28D whereas it is decreased in T28A (see publication “Signal transduction at the 
domain interface of prokaryotic pentameric ligand-gated ion channels” in the Appendix). To investigate 
possible structural rearrangements in the ELIC mutant T28D, the mutant was recombinantly expressed 
in E.coli. After lysis of the cells, the protein was extracted in the detergent UDM and purified by IMAC. 
After cleavage with the HRV 3C protease the His-MBP fusion protein was removed by an additional 
IMAC step and the concentrated protein was subjected to SEC (Figure 64). A peak with a retention 
volume of 11.8 ml corresponded to ELIC, as confirmed by SDS-PAGE. 
 
Figure 64 Size exclusion profile of ELIC T28D 
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Size exclusion chromatogram of the mutant ELIC T28D. Whereas the void peak elutes at 8.34 ml, the peak 
corresponding to the ELIC T28D elutes at 11.84 ml. The black bar shows the fraction which was loaded on SDS-
PAGE. 
 
The purified ELIC mutant was subsequently supplemented with 0.05 mg/ml E.coli lipids and crystallized 
at a concentration of 7.8 mg/ml in in 1 M (NH4)2SO4, 0.05 M ADA pH 6.5, 11 % - 16 % PEG4000 and 
0.05 M ADA pH 6.5, 0.1 M LiSO4, 0.1 M NaSO4, 11 %- 16 % PEG4000 with and without addition of 
cysteamine. Crystals were harvested, cryopotected by addition of 30% Ethyleneglycol and flash frozen 
in liquid propane. Data was collected at the X06SA beamline at the Swiss Light Source of the Paul 
Scherrer Institute and structures were subsequently determined at 4.5 Å in the absence and 9.5 Å in the 
presence of the agonist cysteamine. In both cases they showed the already known non-conductive state 
of the protein (although in case of the ligand complex, the resolution is too low to make a definitive 
assignment). Thus, regardless of the strong impact of the mutant on channel function, ELIC crystallized 
in the usual non-conductive conformation which underlines the stability of this state (Figure 65). 
 
Figure 65 Cartoon representation of ELIC wild type and T28D mutant and statistics 
A) Superimposition of a single subunit of the ELIC wild type (cyan) and the T28D mutant (red). The mutant channel 
shows the same non-conducting conformation. B) Statistics of the crystallized mutant channel with and without 
agonist. 
 
2.2.3 The tip of the β1-β2 loop 
In GLIC, as well as in the agonist-bound structure of GluCl, the β1-β2 turn of the extracellular domain 
and the α2-α3 loop of the pore domain are in direct contact. In GLIC, a lysine at the tip of the β1-β2 turn 
interacts with a conserved proline of the α2–α3 loop via the protein backbone. In ELIC, where the tip of 
the β1-β2 turn is formed by a leucine, and in other channels residing in a non-conductive conformation, 
such as the ligand-free GluCl, the contact is broken and these residues are approximately 7 Å apart 
from each other (Figure 66). 
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Figure 66 Cartoon representation of the domain interface of GLIC and ELIC. 
In GLIC (green) the lysine, located at the tip of the β1-β2 loop interacts with a proline in the α2-α3 loop. In ELIC 
(cyan) the tip of the β1-β2 loop is occupied by a leucine, which makes no direct contact with the proline located in 
the α2-α3 loop. The Figure was created with Pymol. 
 
To examine the importance of this interaction for activation, the tip residues Lys32 in GLIC and Leu29 
in ELIC, were mutated to either alanine or glycine. Additionally, to prevent any interactions between the 
two domains, in another set of mutants, these residues were deleted. The mutant channels were 
subsequently expressed in X. laevis oocytes and characterized by TEVC electrophysiology and with an 
oocyte surface expression assay. Both assays were carried out in parallel with the same batch of 
oocytes to have comparable signals. Upon mutation of the residue at the tip of the turn to alanine, both 
mutant channels can still be activated by agonists, but with a much lower maximum current compared 
to the wild type protein. The mutation to glycine results in nearly complete loss-of-function in both 
proteins (Figure 67). If deleted in ELIC, the dL29 mutant can still be activated, whereas the 
corresponding deletion in GLIC causes a nonfunctional channel. The correlation of expression to the 
maximum evoked current of the mutants of Lys32 in GLIC and Leu29 in ELIC, show, that all mutations 
impact gating to variable degrees (Figure 67, A-D). 
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Figure 67 GLIC wild type, Lys32 mutants and ELIC wild type and Leu29 mutants. 
A) Maximum currents of X. laevis oocytes expressing GLIC wild type and different mutants of Lys32 compared to 
non-injected oocytes. Currents were measured at pH 4 and the voltage was clamped at -40 mV. The black bar 
indicates currents of 2 µA. B) Maximum currents of X. laevis oocytes expressing ELIC wild type and different 
mutants of Leu29, compared to non-injected oocytes. Currents were measured at 25 mM cysteamine and the 
voltage was clamped at -40 mV. The black bar indicates currents of 5 µA. C) Expression of GLIC wild type and the 
mutants K32A, K32G and deletion of K32 on the surface of X. laevis oocyte detected by an anti-hemagglutinin-
antibody. D) Expression of ELIC wild type and the mutants L29A, L29G and deletion of L29 on the surface of X. 
laevis oocyte detected by an anti-hemagglutinin- antibody. E) Relationship between expression and activity of GLIC 
wild type in comparison to the mutants K32A, K32G and the deletion of K32. F) Relationship between expression 
and activity of ELIC wild type in comparison to the mutants L29A, L29G and the deletion of L29. Data show averages 
of at least 10 oocytes and are normalized to wild type, the errors are SEM. 
 
In Figure 67, C, the expression levels of GLIC WT and mutants on oocyte membranes compared to non-
injected oocytes is shown. The mutant K32A even expressed at a higher level than wildtype, whereas 
the glycine mutant K32G and the deletion dK32 show reduced expression levels. By correlating these 
levels with the maximum current evoked during TEVC measurements, the alanine mutant, which 
showed the highest expression levels results in a strongly decreased activity. The normalized activity in 
the glycine mutant is about 40 % of the WT, but considering the low expression this value has to be 
taken with caution (Figure 67, D). Also for ELIC mutants the expression levels are reduced compared 
to the wild type protein, particularly in the alanine mutant L29A, which only shows about 20% of the 
expression of WT. When related to the maximum current, the normalized activity of the alanine mutant 
L29A as well as the deletion mutant dL29 is about 30% of the wild type protein (Figure 67, E). 
To correlate expression and activity on the level of individual cells, for each oocyte the maximum 
currents evoked by WT and mutant channels measured by TEVC electrophysiology was plotted against 
the expression level measured by a surface assay (Figure 68). Compared to their expression the current 
response of the 3 mutants is generally small (Figure 68, A). Although the K32A mutant of GLIC has a 
similar expression level as the WT, as seen by the similar distribution, the currents are significantly 
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reduced. A similar relationship is observed for ELIC mutants (Figure 68, B). These findings underline 
the importance of these tip residues for function in both homologues. 
 
Figure 68 Correlation of maximum current and expression of mutants of the tip of the β1- β2 turn. 
A) The expression of GLIC wild type (red), and the tip mutants K32A (grey), K32G (yellow) and the deletion dK32 
(dark blue) in single X. laevis oocytes was quantified by a surface assay detecting the fused hemagglutinin tag. The 
expression is shown in comparison to non-injected oocytes (light blue).The maximum current of each oocyte was 
measured by two electrode voltage clamp and related to the expression level. B) Correlation of expression and 
maximum currents for ELIC wild type (red) and the tip mutants L29A (grey), L29G (yellow) and the deletion dL29 
(dark blue) for single X. laevis oocytes expressing the respective constructs. 
 
2.2.4 Summary 
 
By mutation of residues located in the domain interface between the extracellular and the 
transmembrane domain of GLIC and ELIC and subsequent characterization by biochemical and 
electrophysiological methods, several positions were identified to play an important role in channel 
gating. For GLIC, mutations causing a loss of function protein lie in the β1-β2 loop (D31), in the β6-β7 
loop (F115) and in the α2- α3 loop (D121, L245A, T248A, Y250A), whereas the mutation of a conserved 
arginine at position 191 (β10-α10 linker) resulted in a misfolded protein. These findings underline the 
importance of those residues for channel gating. Mutating the tip residue of the β1-β2 loop (K32) to 
alanine or glycine, the channel activation is affected but not prevented. Only if the leucine is deleted, the 
channel function is impaired. For ELIC a similar picture can be drawn. Residues resulting in a loss of 
function protein when mutated lie in the β6-β7 loop (F116), in the β10-α1 linker (R199) and in the α2- 
α3 loop (D122, L253A, L256A, Y258A). The residues in the β1-β2 loop (T28 and L29) show a slightly 
different behavior when mutated. Whereas in GLIC the D31 (in the β1-β2 loop) forms a salt bridge with 
the arginine at position 191, in ELIC this connection does not exist. The mutation of the corresponding 
residue (T28) to alanine causes reduced maximum currents in TEVC measurements. The introduction 
of an aspartate at this position, thereby providing a possible partner for a salt bridge results in reduced 
currents as well. The crystal structure of this mutant protein still shows the familiar non-conductive 
conformation, despite the big impact on function. In GLIC a charge reversal mutant of the salt bridge 
was created, where the arginine (R191) and the asparagine (D31) were switched, which resulted in a 
channel with impaired function and a tilt of the pore lining helix in the crystal structure. In ELIC a similar 
switch of the arginine in the β10-α1 linker (R199) with the mutated T28D in the β1-β2 loop caused the 
protein to aggregate. Similar to GLIC, the tip residue of the β1-β2 loop (L29) of ELIC was mutated to 
alanine and glycine and in another step, deleted. Whereas the alanine mutant and the deletion show 
reduced currents, the glycine mutant results in a loss of function protein. 
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In this study, several residues were identified to play an important role in channel gating. Notably, the 
residues causing a loss of function when mutated to alanine, all lie in the in close proximity to each 
other, indicating that the intactness of this region, the total charge and the interaction between residues 
are mandatory for function. Since most mutations in both homologues, GLIC and ELIC, showed similar 
phenotypes the importance of this conserved part of the protein is accentuated. 
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3. Discussion 
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After the discovery that the nicotinic acetylcholine receptor (nAChR) from the electric organ of 
electrophorus electricus converts a chemical input into an electrical output [121], this protein and 
homologous pentameric ligand gated ion channels (pLGICs) were studied extensively by biochemical 
and electrophysiological methods. Thirty-five years later, prokaryotic homologues were identified [24, 
41] leading to the first structure determination of a full length pLGIC [26, 27, 32] at high resolution. 
The structure of the prokaryotic homologue GLIC from Gloebacter violaceus was determined in a 
supposedly open conformation, whereas ELIC from Erwinia chrysanthemi was crystallized in a 
nonconductive state [26, 27, 32]. Because so far it was not possible to determine the structure of GLIC 
and ELIC in another conformation at high resolution, a part of this work was devoted to the selection of 
specific binding protein, which could stabilize the ion channels in a defined state [57]. Most proteins 
described here were identified in vitro from synthetic libraries. Ribosome and Phage Display allowed the 
successful selection of 10 different single-chain variable fragments (scFvs) and 27 different designed 
ankyrin repeat proteins (DARPins) recognizing GLIC. For GLIC, the selection was carried out at slightly 
basic pH in conditions where the protein is supposed to adopt a non-conductive state. Certain binders 
should therefore specifically bind the agonist-free conformation of the target protein, which was partly 
confirmed by an ELISA. The same strategy to select binders that recognize the ligand bound open 
conformation of ELIC was not feasible, since ELIC cannot be activated in detergent solution. Although, 
proteins binding to this channel were successfully identified, most DARPins and some nanobodies, 
which were selected for ELIC show unfavorable biochemical characteristics and unspecific binding. 
 
3.1 Selection of specific binding proteins 
By using a synthetic library encoding for scFvs a total of 10 unique binders targeting GLIC were selected 
by Phage Display. In this selection, the protein scFv A was the dominating species that was identified 
33 times in different clones, whereas other binders, such as scFv H, were found only once. This behavior 
could correlate with the binding affinity of the respective scFv to its target. The stronger a scFv binds, 
the more likely the associated phage can be rescued and used for infection of the bacteria in the next 
round of selection. Surprisingly, the quantification of binding affinities by SPR revealed that the 4 scFvs, 
which were found to co-elute with GLIC on SEC, all bind with affinities in the same range. An alternative 
explanation for the prevalence of scFvA during selection could be a bias of the original library for this 
scFv. Although the comparison of the sequences of the randomized CDR3 of the scFvs that bind with 
low KD to the targeted GLIC, does not show a clear preference for certain amino acids, trends are 
apparent. In general, it appears that glutamine, leucine and threonines located in the heavy chain CDR 
3 are important for binding, whereas in all selected scFvs hydrophobic residues in the heavy chain CDR 
3 are overrepresented (Table 1). Furthermore the DPL16 light chain seems to more suited for binding 
GLIC than the DPK22 light chain, because only one scFv was selected carrying this chain. Despite the 
high affinity and specificity of the selected scFvs to GLIC and a broad screening of crystallization 
conditions, no crystals of a scFv-GLIC complex were obtained, even at low pH in conditions where GLIC 
normally crystallizes, which suggests that the scFvs prevent crystallization. Since binding of the scFvs 
appears to be pH independent, the epitope may not involve protonatable residues and may also not 
undergo large pH-dependent conformational changes. Whereas the comparison of the structure of GLIC 
crystallized at low pH and a locally closed conformation of a mutant of the same protein shows significant 
structural differences only in the pore region, bigger conformational changes occur when GLIC is 
crystallized at neutral pH where it is supposed to be in a non-conductive conformation. A collective 
quaternary reorganization is observed in the extracellular domain involving radial and tangential motions 
affecting not only the C-loop (agonist binding site) but also the β7-β8 loop (B-loop, Figure 69) [26, 35, 
36]. 
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Figure 69 Side view of a full-length monomer of GLIC 
Superimposition of the open pH 4 (green) and closed pH 7 (red) GLIC structures, the black arrows show the direction 
of the motion from the closed form to the open form. Adapted from [36]. 
 
Another reason for the poor crystallization properties of the complex could be related to the flexible linker 
connecting the two variable parts of a scFv, which may interfere with the formation of crystal contacts. 
In order to decrease the protein flexibility for co-crystallization, the scFvs were cloned into a Fab scaffold. 
Although the Fabs bind with similar affinities, co-crystallization experiments were also in this case not 
successful. However, because of their bigger size, Fab fragments can be used as tools for single particle 
electron microscopy by increasing the molecular weight of the protein-complex. This strategy was used 
in a recent structure of an ABC transport protein determined by electron cryo-microscopy [122]. 
Another promising scaffold for protein binders are DARPins [78], which in this study were selected by 
Ribosome Display. The 27 DARPins, selected for GLIC from a DARPin library of the 2nd generation 
[111], were characterized with respect to their binding properties. All selected DARPINS contained a 
N3C scaffold and eight of them showed high binding affinities in the nanomolar range. In Figure 70, their 
sequences are aligned. 
 
Figure 70 Alignment of DARPins with high affinity to GLIC. 
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The top sequence (DARPin N3C) corresponds to the consensus sequence. X indicates randomized positions in the 
library, the dots identical residues. 
The DARPins G16, G18 and G51 contain identical residues in the randomized position of the internal 
repeats, but different residues in the N-terminal cap, which could indicate that the internal repeats bind 
the same epitope. Interestingly, whereas the DARPins G16 and G18 co-migrate with GLIC on a size 
exclusion column, G51 does not, despite the high sequence conservation, which underlines the 
importance of the contribution of residues of the N-terminal cap for binding (Figure 71). 
Figure 71 Alignment of DARPin G16, G18 and G51 
The top sequence (DARPin N3C) corresponds to the consensus sequence. X indicates randomized positions in the 
library, the dots identical residues. 
 
The DARPins selected for GLIC by Ribosome Display, bind specifically at neutral or slightly basic but 
not at acidic pH, as confirmed by ELISA. This pH dependence could either be due to the involvement of 
ionic interactions, which would be weakened upon protonation, or be dependent on the state of the 
channel, assuming that in the detergent solubilized state, GLIC can adopt different conformations [49, 
51]. Supposing that GLIC shows a similar activation mechanism as other pLGICs, during binding of the 
ligand in the C-loop region, the loop would cap the binding site thereby transmitting a signal to the 
transmembrane part to promote channel opening [123]. If the DARPins bind to the extracellular (ECD) 
part of GLIC, they could specifically recognize an agonist-free conformation of the ligand binding 
domain, but the oocyte binding assays did not show any evidence for binding from the extracellular side. 
Attempts to express DARPins as YFP fusions together with GLIC in HEK-293 cells did not show any 
enrichment of YFP to the membrane, thus also the binding to the intracellular part of GLIC could not be 
demonstrated. Future experiments could use HEK-293 cells expressing GLIC to probe binding of 
purified YFP-DARPins from the outside. Although a similar experiment with X. laevis oocytes did not 
show any binding, the difference of the membrane composition of HEK-293 cells and the absence of 
the vitelline layer, a thick layer of extracellular matrix, might ease the access of the binders to their site. 
If binding of DARPins or other specific protein binders would be detected in a binding assay, a potential 
effect on channel function by either occupying an agonist binding site or preventing conformational 
changes upon channel gating [53-55], could be explored by patch-clamp electrophysiology. 
Almost all DARPins selected by Ribosome Display to recognize ELIC, showed formation of higher 
oligomers and unspecific binding to the protein. Since Ribosome Display was performed in presence of 
neutravidin, or in the last round with streptavidin coated beads, it could be that binders were selected 
against avidin, despite the fact that each cycle was preceded by a prepanning step to prevent binding 
to this protein. From the DARPins sequences, the cause for unspecific binding or oligomerization is not 
immediately apparent, since most of them contain similar residues at randomized positions as the 
DARPins selected for GLIC. Only few of the binding proteins were found to contain long insertions. 
The nanobodies, which were obtained by immunization of alpacas with the protein of interest followed 
by the generation of a phage display library and selection by Phage Display show better biochemical 
properties than the DARPins. Selected nanobodies were monomeric and co-eluted with ELIC on SEC 
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after complex formation. However, during SPR analysis, it was found that certain nanobodies bind 
unspecifically to the chip surface consisting of avidin and alginates, resulting in a high background even 
in the absence of ELIC. Because it was suggested that the conformational changes in ELIC do not 
symmetrically affect all subunits and that pLGICs can adopt different conformations even in the absence 
of any ligand [49, 51], it could be, that conformational changes in ELIC are rapid and that the protein 
does not remain long enough in a single state to be recognized by specific binders. 
Since, similar as for the binders recognizing GLIC, it was not possible to investigate the binding of the 
nanobody to ELIC expressed on X. laevis oocytes, a possible impact of the nanobodies on the function 
of ELIC will have to be studied by patching of HEK-293 cells expressing the channel. 
Although in the course of this thesis the selection of several different specific binders targeting GLIC 
and ELIC in vitro and in vivo was successful, none of them allowed to obtain crystals of sufficient quality 
for structure determination. Since no impact of these binders on the function of the target protein could 
be detected either, because they were not binding to the channels expressed in X.laevis oocytes, a 
different approach to investigate the gating mechanism was used as described in the next chapter. 
 
3.2 Functional characterization of GLIC and ELIC 
Previous studies have identified the interface between the extracellular and the transmembrane 
domains of pentameric ligand-gated ion channels as an important part of the channel opening process, 
since it may transduce conformational changes in the extracellular domain in response to agonist 
binding to the pore region [42, 43, 124]. The domain interface is highly conserved among pro- and 
eukaryotic family members. Overall, the prokaryotic homologues GLIC and ELIC share less than 30% 
of identical amino acids. The biochemical and electrophysiological investigation of GLIC and ELIC 
mutants of various positions in the domain interface of the extracellular and the transmembrane domain 
allowed the identification of residues that had a similar functional effect on both channels. Several 
residues at the interface located on loop regions in either domain were mutated and the expression on 
the surface of Xenopus laevis oocyte was quantified with a biochemical assay recognizing a tag exposed 
to the outside. In parallel the functional behavior of the mutants was analyzed by two-electrode voltage 
clamp electrophysiology. Most mutants showed similar expression levels in oocytes as the 
corresponding wild type protein, thus suggesting that the channels, despite the mutation, fold properly. 
None of the alanine mutants showed increased basal activity without application of agonist, which can 
be explained by either a possible stabilization of a non-conductive conformation of the channel or by a 
potential uncoupling of the extracellular and the transmembrane domain. Calorimetry experiments with 
two non-activatable ELIC mutants demonstrate, that the mutant proteins show comparable ligand 
binding affinities as the wild type protein, which suggests that the mutations do not interfere with ligand 
binding and instead affect channel gating (see publication “Signal transduction at the domain interface 
of prokaryotic ligand-gated ion channels” in the Appendix). 
Despite the low sequence identity between GLIC and ELIC, most of the mutations had a similar impact 
on channel function in both homologues, thus indicating, that both proteins share a common signal 
transduction mechanism that may be general for the family. The amino acids that, if mutated, cause a 
loss of function in both homologues, mainly cluster at two regions of the channels, namely in the β6-β7 
loop of the extracellular domain and in the α2-α3 loop of the transmembrane part. Mutations of 
conserved residues of the β1-β2 loop and the connection between β10 and α1 also have a strong impact 
on function. In Figure 72 a sequence alignment of loops at the interface of GLIC, ELIC, the acetylcholine 
receptor α7nAChR and the glycine receptor is shown, where the conserved parts of the proteins are 
apparent. 
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Figure 72 Sequence alignment of the domain interface 
Sequence alignment of the domain interface of GLIC, ELIC, α7nAChR and GlyR. Residues are coloured according 
to the following properties: Red, conserved residues; green, similar residues; orange, mutations causing a loss of 
function; blue, mutations reducing maximum currents and expression; violet, mutation causing misfolding of the 
protein. 
 
The findings presented in this work are supported by previous studies of the glycine receptor where the 
central role of the highly conserved β6–β7 loop (cys-loop in eukaryotes) for channel gating was 
demonstrated. Mutations causing a decrease in function of the GlyR concern the same positions that, 
upon mutation, resulted in a loss-of-function of the prokaryotic homologues [118]. The β6–β7 loop 
interacts with the α2-α3 loop of the pore domain and a mutation in the latter was identified to be crucial 
for function of the α7-nAChR [125]. Mutations in this loop inhibit channel function but have no effect on 
ligand binding [125] . A different study using chimeras of the acetylcholine binding protein and the 
serotonin receptor underlines the importance of these loops for function as well [124]. In the 
acetylcholine receptor the β6-β7 loop is interacting not only with the α2-α3 loop but also with residues 
from the β1-β2 turn and the β10-α1 linker [43], which emphasizes the importance of this part of the 
protein for channel gating. In GLIC the aspartates of the β1-β2 turn (D31) and the β6-β7 loop (D121) 
interact with Arg 191 of the β10- α1 linker. Mutation of these aspartates to alanine cause a loss of 
function phenotype, similarly to the mutation of equivalent aspartates in the β6-β7 loop of the nAChR, 
the glycine and the serotonin receptor, which all had a similar impact on gating by preventing channel 
activation [120, 126-128]. For GLIC, the mutation of the arginine of the β10-α1 linker, that is part of the 
salt bridge, results in a misfolded protein, which is not transported to the surface of the oocyte as 
confirmed by an oocyte surface assay. This finding underlines the importance of this ionic interaction 
for channel folding and gating similar to studies with the nAChR and other pLGICs [129]. 
In ELIC the residue equivalent to the aspartate in the β1-β2 loop is a threonine (Thr 28), which is not 
capable of forming a salt bridge with the arginine in the β10-α1 linker. Whereas in ELIC the alanine 
mutations of corresponding amino acids of the β6-β7 loop and the β10-α1 linker (i.e. Asp122 and 
Arg199, respectively) resulted in a loss of function protein, the T28A mutation resulted in lower maximum 
currents measured by TEVC electrophysiology. This indicates that during channel opening the polar 
side chain of the threonine plays an important role. By mutating this threonine to an aspartate, a 
negatively charged amino acid present in other family members including GLIC, a possible partner for 
formation of a salt bridge between the β1-β2 loop and the β10-α1 linker was introduced. In this study it 
was shown that in this mutant the maximum current upon agonist application is low, and after correlating 
it to the expression level obtained from the oocyte surface expression assay, it appears that the 
maximum current response is only 20 % of the values obtained for the wild type channel. This indicates 
that channels might already be in a desensitized state, which could account for the low maximum 
response of the mutant expressed in X. laevis oocytes. Assuming that the T28D mutation establishes 
an ionic interaction between the aspartate and R199, as observed in GLIC, it could lead to destabilization 
of the resting state and therefore result in a higher potency of the agonist. This was confirmed in 
isothermal titration calorimetry (ITC) experiments with the mutant T28D, which showed an increased 
affinity to the agonist compared to wild type. For T28D also the half maximal effective concentration 
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(EC50) of channel activation, measured by two-electrode voltage clamp, was shifted towards lower 
agonist concentration. Furthermore, residual activity even without agonist was observed in patch clamp 
recordings (see publication “Signal transduction at the domain interface of prokaryotic pentameric 
ligand-gated ion channels” in the Appendix), which suggests that ELIC can undergo conformational 
changes leading to channel opening even without agonist as predicted by the Monod, Wyman and 
Changeux model [50, 51, 123]. Supposing that the T28D mutation shifts the probability of the channel 
residing in different states, the hypothesis that a fraction of the channels is already desensitized, and 
thus does not contribute to the measured currents, is plausible. Taken together these findings suggest 
that the basic side chain of the arginine is mandatory for function in all channels, whereas the mutation 
of the polar threonine in ELIC, although important for function, does not inhibit channel gating 
completely. 
The big increase in the ligand affinity observed in functional investigations made the T28D mutant an 
attractive candidate for studying a different conformation of the channel. Thus, the crystal structure of 
the T28D mutant at 4.5 Å resolution was determined. In this crystal structure, no tight salt bridge could 
be observed, which would have changed the conformation of the channel and the protein instead 
showed the known non-conductive state of wild type. Although the exact relation of the of the ELIC 
structure to functional states (closed, desensitized or an intermediate) is not known, the structures of 
the glycine receptor bound to its antagonist and GluCl without any ligands resemble ELIC [32, 38] [130], 
which makes its assignment as a resting state plausible. Since ITC and crystallization experiments are 
conducted with detergent purified protein whereas the functional investigations are carried out in a 
membrane, differences in channel behavior can be attributed to the absence of a lipid environment. 
The mutation of the corresponding residue in the β1-β2 loop of GLIC (D31A) resulted in a complete loss 
of function of the channel, thus underlining the importance of an acidic site chain at that position to form 
a salt bridge between the β1-β2 turn and the β10-α1 linker in this channel. Assuming that, analogous to 
ELIC T28A, the affinity of the mutant channel (D31A) to the ligand is decreased, it might still be possible 
to activate this non-functional GLIC mutant at even lower pH. 
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Figure 73 Superimposition of the GLIC charge reversal with GLIC WT and ELIC WT 
A) Superimposition of one subunit of GLIC (green) and the charge reversal mutant (blue) in two different 
orientations. A close-up of the interface is shown left. Mutated residues are displayed as spheres. B) Superposition 
of a subunit of the charge reversal mutant (blue) and ELIC (cyan) with a close-up of the pore domain shown left. 
The Figure was created with Pymol. 
 
To further investigate the importance of the described ionic interaction, double mutations of ELIC and 
GLIC were constructed, where the positions of the interacting acidic and basic residues was switched 
(charge-reversal mutation). Similar charge-reversing mutations have been previously studied in the 
acetylcholine receptor, where the single mutants had reduced gating equilibrium constants whereas the 
double mutant showed wild-type like gating characteristics [21, 23, 120]. Whereas the ELIC charge 
reversal mutant, when expressed in E. coli, could not be purified, due to aggregation of the protein, the 
GLIC mutant was crystallized at conditions with low pH and the structure was determined at 3.2 Å. This 
structure revealed striking differences in the pore region compared to GLIC WT. In GLIC WT and in the 
agonist bound structures of the glycine and glutamate receptor (GlyR and GluCl, [10, 37]), the α2- 
helices show the same, apparently open, conformation, whereas in the charge reversal mutant the C-
terminal part of the α2-helix seems to have collapsed towards the symmetry axis, thereby blocking the 
pore (Figure 73, A). A comparison of this GLIC mutant with ELIC shows that the upper part of the α2-
helix of the charge reversal mutant is oriented similarly to that of ELIC (Figure 73, B) but the lower part 
is less bent. 
Interestingly the structure of this charge reversal mutant resembles previously crystallized GLIC 
mutants. Both the P246G and the Y250A mutant of GLIC show a similar orientation of the pore lining 
helix, which is partially unfolded close to the α2-α3 linker and tilted, thereby obstructing the channel. 
Comparable conformations, termed “locally-closed”, were also observed for GLIC mutants were the 
cysteines in the β1-β2 and the α2-α3 loop were crosslinked and of a structure of GLIC crystallized at 
neutral pH. In Figure 74 a superimposition of the charge reversal mutant of GLIC and the P246G mutant 
as well as with a cysteine crosslinked mutant are shown. Whereas these mutants all have a similar 
orientation of the pore lining helices, their functional behavior is different. The charge reversal mutation 
of GLIC results in a loss-of-function, whereas the P246G mutant can still be activated (see publication 
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“Signal transduction at the domain interface of prokaryotic pentameric ligand-gated ion channels” in the 
Appendix, [36]). Thus, although the salt bridge interaction is preserved in the charge reversal mutant, 
the pore is in a closed conformation and cannot be activated by lowering the pH. 
 
Figure 74 Superimposition of the charge reversal mutant with the locally closed conformation of GLIC and 
P246G 
A) Superimposition of a subunit of the charge reversal mutant (blue) and the locally closed conformation (H11’F, 
LC1 subtype) of GLIC obtained by cysteine crosslinking between the β1-β2 and the α2-α3 loop. B) Close-up of the 
interface of a superposition of a subunit of the charge reversal (blue) and the P246G mutant (orange). Mutated 
amino acids are shown as spheres. The Figure was created with Pymol. 
 
Although the above-mentioned salt bridge is present in structures of GLIC and of the nicotinic 
actelylcholine receptor and its formation and disruption is important for channel gating [26, 42], it is 
probable not involved in the main pathway of gating. This is underlined by findings of mutation analysis 
of the nAChR where the corresponding residues were mutated (charge changing and charge reversal) 
but still show activation [119]. 
In the position next to the described aspartate, at the tip of the β1-β2 loop of the extracellular domain, a 
lysine (K32), interacts via its backbone with a highly conserved proline (P256) in the α2-α3 loop of the 
pore domain. In ELIC, containing a leucine (L29) at the equivalent position, this interaction is not formed. 
Since equivalent interactions are present in other pLGICs that were crystallized in presumably open 
conformations and not in structures adopting a non-conductive state, it was assumed, that this 
interaction may play a role in channel gating [26, 52]. The mutation of the proline to alanine resulted in 
channels that still could be activated, although with a lower maximal response than the wild type protein. 
The mutation of the tip residues in the β1-β2 loop to glycine caused a loss of function phenotype in ELIC 
whereas the corresponding mutation in GLIC was functional. Whereas the deletion of the lysine in GLIC 
resulted in inactive channels, in ELIC, the deletion of the equivalent residue L29 only caused a reduction 
in the maximal current. These findings suggest that the interaction between the tip of the β1-β2 loop and 
the proline in the α2-α3 loop is not the predominant transducer of conformational rearrangements upon 
agonist binding to the transmembrane part, since even drastic mutations do not abolish activation. 
In summary, the data presented in this thesis and in an accompanying publication demonstrate that 
channel activation cannot be reduced to a single critical contact between the two domains of the protein. 
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Instead, this process involves several residues that cluster at the interface between the extracellular- 
and the pore domain, which all play an important role in gating. Generally, it could be shown that the 
loops and linkers that were suspected to play a central role in eukaryotic channels are also essential for 
the prokaryotic homologues GLIC and ELIC. The detailed effects of equivalent mutations in 
heteropentameric eukaryotic receptors might be less drastic because subunits that were not mutated 
could compensate for the change. Despite these differences, it appears that the gating mechanism is 
conserved within pLGICs and the prokaryotic homologues GLIC and ELIC thus can be used as model 
system for the investigation of functional properties that are general for the family. 
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4.1 Buffers and media 
Barth’s solution:  88 mM NaCl, 1 mM KCl, 1 mM CaCl2, 0.33 mM Ca(NO3)2, 0.82 mM MgSO4, 
10 mM Na-Hepes (pH 7.4) 
EB:   50 mM Tris-acetate pH 7.5 at 4 °C, 150 mM NaCl, 50 mM EDTA 
Minimal medium: 54 g Na2HPO4, 24 g KH2PO4, 4.02 g NaCl, 7.98 g NH4Cl, pH 7.4, MgSO4, 
CaCl2, Glucose 
ND96:    93.5 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 2 mM MgCl2 and 10 mM Hepes (pH 
   7.4) 
Lysogeny Broth (LB):  5 g yeast extract, 10 g tryptone, 5 g NaCl per liter 
PBS:    137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, pH 7.4 
TBS:    0.05 M Tris, 150 M NaCl, pH 7.6 
Terrific broth (TB):  12 g tryptone, 24 g yeast extract, 4 ml glycerol per liter, supplemented with 0.17 
M KH2PO4 and 0.72 M K2HPO4 
TYE:    10 g bacto tryptone, 5 g yeast extract, 8 g NaCl, 15 g agar per liter 
WBT:    50 mM Tris-acetate, pH 7.5 at 4 °C, 150 mM NaCl, 50 mM MgAc 
WBT (E):  50 mM Hepes, pH 7.5, 150 mM NaCl, 50 mM MgAc 
2YT:    16 g bacto tryptone, 10 g yeast extract, 5 g NaCl per liter 
 
 
4.2 Expression and purification 
4.2.1 GLIC and ELIC 
GLIC cloned in a pBX_His_MBP_3C vector was transformed into competent MC1061 cells and grown 
at 37 °C in Terrific Broth (TB) medium supplemented with 100 µg/ml ampicillin. By addition of 0.04 % L-
arabinose, overexpression of GLIC was induced overnight at 20 °C. All the following steps were carried 
out at 4 °C. The cells were harvested, resuspended in a buffer (50 mM Hepes pH 8, 150 mM NaCl) 
containing 1 mg/ml lysozyme, protease inhibiors (EDTA free, Roche), 40 μg/ml DNase and 1 mM MgSO4 
and lysed with an Emulsiflex C3 high-pressure homogenizer (Avestin) at 35 kpsi. The membranes were 
harvested by ultracentrifugation with a 45 TI rotor (Beckmann) at 40,000 rpm for 1 h and the 
overexpressed GLIC was extracted with a buffer (50 mM Hepes pH 8, 150 mM NaCl) supplemented 
with 1 % DDM (n-Dodecyl-β-D-Maltoside, Anatrace). 
ELIC was expressed and purified according to the procedure described previously (Hilf 2008). 
Competent BL21 cells were transformed with a pet26b vector carrying the gene for ELIC. They were 
grown in M9 minimal medium at 37 °C and overexpression was induced by addition of 0.2 mM IPTG 
overnight at 20 °C. All the following steps were carried out at 4 °C. The cells were harvested, 
resuspended in a buffer (50 mM Hepes pH 8, 150 mM NaCl) containing 1 mg/ml lysozyme, protease 
inhibitors (EDTA free, Roche), 40 μg/ml DNase and 1 mM MgSO4 and lysed by sonication. The 
membranes were harvested by ultracentrifugation with a 45 TI rotor (Beckmann) at 40,000 rpm for 1 h 
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and the overexpressed ELIC was extracted with a buffer (50 mM Hepes pH 8, 150 mM NaCl) containing 
1% UDM (Undecyl-β-D-Maltoside, Anatrace). 
Both proteins were purified using the same protocol except for the difference in the detergent, 0.03 % 
DDM in case of GLIC and 0.145% UDM in case of ELIC. The extracted proteins were subjected to 
immobilized metal affinity chromatography (IMAC) purification by batch- binding to Ni-NTA beads in 15 
mM imidazole for 1 h. Unspecifically bound proteins were washed away with buffer (50 mM Hepes pH 
8, 150 mM NaCl) supplemented with 55 mM imidazole. The bound proteins were eluted with high 
amounts (400 mM) of imidazole and the His-MBP- fusion tag was cleaved off with the HRV 3C protease. 
After dialysis to lower the imidazole concentration, a second IMAC purification was carried out to remove 
the HRV 3C protease and the fusion tag. Subsequently the flow-through containing the cleaved target 
protein, was concentrated (Amicon, 30 kDa cut-off) up to 500 µl and subjected to a size exclusion 
chromatography on a Superdex S200 (GE Healthcare). 
The peak corresponding to the elution volume of the target protein was collected and concentrated 
(Amicon, 30 kD cut-off) to the desired concentration. For Ribosome Display, ELISA and surface plasmon 
resonance (SPR) the proteins were expressed with an N-terminal Avi-tag (GLNDIFEAQKIEWHE). After 
the second Ni-NTA purification a biotinylation step (Table 2) with the enzyme BirA overnight at 4 °C was 
performed prior to concentration and size exclusion chromatography. 
µl  Final concentration 
250-500 purified protein ca 100 µM 
62.6 200 mM ATP, pH 7 (NaOH) 5 mM 
8.3 3 M MgOAc 10 mM 
x biotin 1.2 fold of concentration of avi-
tag 
5-8 BirA (8 mg/ml)  
fill up to 2500 200 mM NaCl, 10 % glycerol, 
detergent 
 
Table 2: Pipetting scheme for biotinylation with BirA 
 
4.2.2 Single chain variable fragments (scFvs) and Fabs 
Purification with periplasmic extraction. Competent HB2151 cells were transformed with DNA coding for 
single chain variable fragments (scFvs) in a pHen vector and grown in 2YT medium supplemented with 
0.1 % glucose and 100 µg/ml ampicillin at 37 °C. After inoculation with 1 mM IPTG, expression 
proceeded for 4 h at 30 °C. Subsequently the cells were harvested and resuspended in sucrose buffer 
(20 mM Tris pH 8, 25 w/v % sucrose, 5 mM EDTA, 4 ml per gram of pellet) and incubated for 20 min on 
ice. Cells were centrifuged for 30 min at 20000 rpm and the supernatant saved (sucrose fraction). The 
pelleted cells were resuspended with (3.5-4 ml per gram pellet) 5 mM MgCl2, 1 mM PMSF and 0.6 mg 
per gram cells lysozyme. After incubation for 30 min on ice, the cells were centrifuged (30 min at 20000 
rpm) and the supernatant was saved (lysozyme fraction). The two fractions (sucrose and lysozyme) 
were combined and dialyzed over night against PBS pH 7.4 at 4 °C, using 12-14 kDa MwCO. 
Subsequently, the dialysed sample was loaded on a Protein A column. Unbound proteins were washed 
with PBS buffer and the scFvs eluted with 0.2 M glycine at pH 3. One ml fractions were collected and 
the pH neutralized by adding 70 µl 2 M Tris pH 9. Fractions containing the scFvs were pooled, dialysed 
(PBS, 8000 MwCO cutoff) and subjected to a size exclusion chromatography (superdex S200, GE 
Healthcare). 
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Purification with cell lysis. The scFvs were expressed as described in the previous section. The cells 
were harvested, resuspended in PBS buffer containing 1 mg/ml lysozyme, protease inhibitors (EDTA 
free, Roche), 40 μg/ml DNase and 1 mM MgSO4 and lysed by sonication. Unlysed cells and cell debris 
were removed by centrifugation (8000 g, 30 min, 4 °C) and the supernatant containing the scFvs was 
loaded on a Protein A column. Further purification proceeded as described above. 
Fab fragments. The Fab fragments in a pMX9 vector were produced in MC1061 cells grown in 2YT, 0.1 
% glucose and 35 mg/ml chloramphenicol at 37 °C. After inoculation with 1 mM IPTG overnight at 25 
°C the cells were harvested. The purification was carried out as described for scFvs. 
 
4.2.3 DARPins 
DARPins, selected by Ribosome Display, were cloned into a pBX_His_3C vector for expression and 
purification. Competent MC1061 cells were transformed and grown in TB medium supplemented with 
100 µg/ml ampicillin at 37 °C. After inoculation with 2x10-2 % arabinose and overnight expression at 25 
°C, the cells were harvested, resuspended in a buffer (50 mM Hepes, pH 8, 150 mM NaCl) containing 
1 mg/ml lysozyme, protease inhibitors (EDTA free, Roche), 40 μg/ml DNase and 1 mM MgSO4 and 
lysed by sonication. The following steps were performed at room temperature. The supernatant was 
subjected to IMAC purification by batch- binding to Ni-NTA beads for 1h. The beads were washed with 
a buffer (50 mM Hepes, pH 8, 150 mM NaCl) containing 55 mM imidazole and the proteins eluted at 
high imidazole concentration. During dialysis (8000 cutoff) to lower the imidazole concentration, the His- 
tag was cleaved off with HRV 3C protease. A second Ni-NTA IMAC purification step was carried out to 
remove the HRV 3C protease and the His- tag. The flow-through containing the purified DARPins was 
concentrated (Amicon, 10 kD cut-off) and subjected to size exclusion chromatography on a Superdex 
S200 (GE Healthcare). The peak corresponding to the DARPin was collected and concentrated to the 
desired concentration for further experiments. By using a buffer with 15 % glycerol, the fractions 
containing the purified DARPins could be shock frozen in liquid nitrogen and stored at -80 °C. 
4.2.4 Nanobodies 
The DNA of the nanobodies selected by Phage Display following the immunization of alpacas was 
cloned into a pBAD vector containing an N-terminal PelB signal sequence, a His10-tag, the fusion protein 
MPB and a HRC 3C cleavage site. Competent E.coli MC1061 cells were transformed with the vectors 
and grown in 2.4 L TB medium supplemented with 100 µg/ml ampicillin at 37 °C until they reached an 
OD600 of 0.8. Protein expression was induced with 2x10-2 % L-arabinose and carried out overnight at 25 
°C. The cells were harvested, resuspended in a buffer (50 mM Hepes, pH 8, 150 mM NaCl) containing 
1 mg/ml lysozyme, protease inhibitors (EDTA free, Roche), 40 μg/ml DNase and 1 mM MgSO4 and 
lysed by sonication. The following steps were performed at room temperature. The supernatant was 
subjected to an IMAC purification by batch- binding Ni-NTA beads for 1h. The beads were washed with 
a buffer (50 mM Hepes, pH 8, 150 mM NaCl) containing 55 mM imidazole and the proteins were eluted 
at high imidazole concentration. During dialysis (8000 cutoff) to lower the imidazole concentration, the 
His- tag and the MPB were cleaved off with HRV 3C protease. A second Ni-NTA IMAC purification step 
was carried out to remove the HRV 3C protease and the His-tagged MBP. The nanobodies were 
concentrated (Amicon, 10 kD cut-off) and subjected to size exclusion chromatography (S200, GE 
Healthcare). 
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4.3 Selection of binders 
4.3.1 Phage Display with single chain variable fragments (scFv) 
The ETH-2 Gold phage library from the Neri group was used for Phage Display with GLIC. Three rounds 
of display were performed prior to the total phage ELISA and the single clone ELISA. The Immunotubes 
(Maxisorb ImmunoTM Tubes, Nunc) were coated with 5 ml of 67 nM neutravidin in 1xPBS, sealed with 
parafilm and incubated overnight at 4 °C. The next day, the tubes were blocked with 5 ml PBS 
supplemented with 0.2 % BSA for 2 h at room temperature. Approximately 500 nM of the biotinylated 
target protein was added in 4 ml PBS, BSA and detergent and incubated for 1 h at 4 °C. After washing 
the tube 3 times with PBS-detergent, 4 x 250 µl of each sub-library in PBS-detergent was incubated for 
2 h at 4 °C. The tube was rinsed 10 times with PBS-detergent and subsequently the phages were eluted 
by adding 500 µl of freshly prepared 100 mM TEA (8 min rotating). The solution containing the 
specifically bound phages was poured into 250 µl of 1 M Tris pH 7.4 for neutralization. A second elution 
step with 500 µl of 200 mM glycine pH 2 was performed. The two elutions were combined, supplemented 
with 45 µl of 2 M Tris for neutralization and stored on ice until further use. 
The eluted phages were heated to approximately 37 °C and 10 ml of a E. coli TG1 cell culture in 2xTY 
in the exponential grow phase (OD600=0.4-0.5) were added. After incubation for 30 min at 37 °C the cells 
were shaken for another 30 min at 37 °C. Subsequently, the cells were centrifuged (10 min, 3300 g, 4 
°C), resuspended in 1-2 ml 2xYT medium, and plated on at least 4 square TYE-glucose-ampicillin plates. 
A serial dilution of the cells with 10-1/-2/-3/-4/-5/-6 time concentrations was performed to proof the enrichment 
of binders during the selection. 10 µl aliquots were spotted on a TYE-plate supplemented with 0.1 % 
glucose and ampicillin. Uninfected TG1 cells served as negative control. After an overnight incubation 
at 37 °C, the colonies on the titration plates were counted and compared to the negative control and to 
plates from previous selection rounds. The number of infected TG1 cells should increase during the 
selection procedure. The cells that grew on the square plates were suspended in 2-3 ml 2xTY containing 
15 % glycerol. Fifty ml 2xTY supplemented with glucose and ampicillin was inoculated with 10 µl of the 
cell suspension to an OD600 of 0.1 and grown at 37 °C to an OD600 of 0.4-0.5. Ten ml of this culture was 
then infected with 10 µl helper-phage (E.coli:helperphage 1:10) and incubated for 30 min at 37 °C. The 
infected cells were centrifuged (10 min, 3300 g, 4 °C) and the pellet resuspended in 10 ml 2xTY medium 
supplemented with ampicillin and kanamycin. 140 ml 2xTY containing ampicillin and kanamycin was 
inoculated with the resuspended cells and grown overnight at 37 °C. 
The cells were centrifuged (10 min, 3300 g, 4 °C) and the supernatant (ca. 160 ml) was mixed with 40 
ml 5xPEG/NaCl (20 % w/v PEG 6000, 2.5 M NaCl) and incubated for 1.5 h on ice. The phages were 
pelleted (30 min, 12000 g, 4 °C) and resuspended in 30 ml PBS. A second purification step was 
performed by adding 7.5 ml 5xPEG/NaCl (30 min on ice) and centrifugation for 30 min at 10000 g. To 
remove remaining cells, the pellet was resuspended in 2 ml PBS and centrifuged for 15 min at 10000 g 
at 4 °C. The supernatant contains the phages in high concentration and can be kept on ice until it is 
used for another selection round, for a total phage ELISA, for infecting cells for single clone ELISA or it 
can be frozen and stored at -80 °C. 
After 3 selection rounds the purified phages were used for infecting E.coli TG1 cells and dilutions (10 -
4/-5/-6) were plated on TYE-plates. Single colonies were picked, grown for 2-3 h at 37 °C in 1 ml 2xTY 
medium supplemented with 0.1 % glucose and ampicillin, and inoculated with 1 mM IPTG. Expression 
was carried out overnight at 30 °C. A crude cell extract ELISA was performed to test the scFv binding 
specificities (see section Crude cell extract). 
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4.3.2 Alpaca immunization and Phage Display with Nanobodies 
Alpacas were immunized every second week with detergent purified target protein. After 4 injections, 
blood was taken and B-lymphocytes were collected. Reverse transcription of the mRNA of the entire 
population of antibodies and nanobodies was performed, and the DNA coding for the nanobodies was 
cloned into a Phage Display library. Subsequently, 2 rounds of Phage Display was performed in a 96-
well plate (Nunc). Eight wells (4 for the target protein and 4 for the negative control) were coated 
overnight with 67 nM neutravidin in 100 µl PBS and subsequently blocked with 250 µl PBS 
supplemented with 2% milk for 2 h at room temperature. 44 µM of the biotinylated target protein was 
added to 4 of the wells in 100 µl PBS containing the appropriate detergent and incubated for 1 h at 4 
°C. The wells were washed twice with PBS-detergent and 10 µl of the phage library (prepared by Y. 
Neldner) in 100 µl PBS supplemented with 1 % milk and the appropriate detergent were added to all 
wells. After incubation of 1 h at 4 °C the wells were washed 5 times and the phages eluted with 100 µl 
trypsin (0.25 mg/ml in PBS), and stored 30 min at room temperature. The eluted phages were 
transferred to a tube containing 5 µl AEBSF (5 mg/ml in H2O) and 200 µl of this solution was used for 
infecting 1.4 ml TG1 cells which were grown to an OD600 of 0.5. After incubation of the cells together 
with the phages for 30 min at 37 °C, 18 ml 2xYT supplemented with 100 µg/ml ampicillin and 2 % glucose 
was added and grown overnight, while shaking, at 37 °C. Simultaneously, a phage titration assay was 
performed to gain information about the amount and enrichment of the phages. Ten µl of the eluted 
phages were mixed with 100 µl PBS and diluted covering a dilution series of 10 -1/-2/-3/-4/-5. 90 µl of TG1 
cells at an OD600 of 0.5 were infected with the serial dilution and 5 µl drops were plated out on LB-agar 
plates supplemented with 100 µg/ml ampicillin and 2% glucose. The total number of phages was 
calculated using following formula: 
#colonies x 10 x 20 x dilution factor x 4 (correction for volume, 400 µl) 
The next day, a glycerol stock (final concentration of 25 % glycerol) of the overnight grown TG1 cells, 
infected with the phages, was prepared and stored at -80 °C. 25 ml 2xTY supplemented with 100 µg/ml 
ampicillin and 2 % glucose was inoculated with 50 µl of the overnight culture and grown at 37 °C until 
OD60 0 of 0.5. 10 ml of this culture was infected with 2x1010 M13KO7 helper phage (prepared by Y. 
Neldner) for 30 min at 37 °C and subsequently centrifuged for 5 min at 4000 rpm. The supernatant was 
removed and the cells resuspended in 50 ml 2xYT supplemented with 100 µg/ml ampicillin and 25 µg/ml 
kanamycin and grown overnight at 37 °C. All following steps were carried out at 4 °C. The next day, the 
culture was centrifuged for 30 min at 4000 rpm and the supernatant, containing the phages was mixed 
with 10 ml 20 % PEG6000 and 2.5 M NaCl. After incubation on ice for 30 min, the mixture was spun for 
30 min at 4000 rpm and the supernatant discarded. The pelleted phages were resuspended in 1 ml PBS 
and remaining cells removed by centrifugation for 5 min at 14000 rpm. A second precipitation was 
performed by adding 250 µl of 20 % PEG6000 and 2.5 M NaCl. The sample was incubated on ice for 
15 min. After centrifugation for 15 min at 14000 rpm, the supernatant was discarded and the pelleted 
phages were resuspended in 1 ml PBS. The phages were used for the next affinity selection round or 
for infection of E.coli TG1 cells for single clone ELISA. To test the titer of the rescued phages, a serial 
dilution covering 10-10 to 10-24 was made. Ninety µl TG1 cells were infected with 10 µl of the diluted 
phages and 5 µl plated out on LB-agar plates supplemented with 100 µg/ml ampicillin and 2 % glucose. 
 
4.3.3 Ribosome Display (according to the protocol from M. Seeger and H. Roschitzki-Voser) 
The first round of Ribosome Display was performed with immunotubes. The second and third round was 
carried out in a 96-well plate, and the fourth round with magnetic streptavidin-beads. We used a library 
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of RNA of DARPins of the second generation [111]. For the selection with ELIC, the buffer WBT (E) was 
used. 
Surface Panning using Immunotubes 
Preparation. The Immunotubes (Maxisorb ImmunoTM Tubes, Nunc) were coated with 1 ml of 66 nM 
neutravidin in 1xTBS (3.3 µl from a 20 µM stock per ml), sealed with parafilm and incubated overnight 
at 4 °C. Two immunotubes are needed for each target protein. Both tubes were blocked with 5 ml 0.5 
% BSA in 1xTBS for 1 h at RT while shaking. The tubes were washed three times with 1xTBS. The TBS 
solution was discarded. One ml biotinylated target protein at ~ 1 µM in WBT-BSA-detergent was added 
to one tube and shaken for 1 h at 4 °C. Just before panning was started, the tubes were washed three 
times with WBT-BSA-detergent. 
In vitro translation. Translation mix was prepared according to pipetting scheme (Table 3). Five times 
volumes for immunotubes were used. 5x 4 µl library RNA à 2.5 µg/µl was added to the translation mix. 
Translation was subsequently carried out for exactly 8 min 30 sec at 37 °C.  The reaction was stopped 
by adding ice-cold WBT-BSA-detergent buffer containing 12.5 µl Heparin (200 mg/ml stock) and sample 
was centrifuged at 20'000 g for 5 min at 4 °C. 
Translation mix µl 
Premix buffer (Red) 25 
Extract 30 
 
Stop solution 
 
WBT-BSA (0.5 % w/v) 220 
Heparin (200 mg/ml) 2.75 
Total 278 
Table 3 Translation pipetting scheme for one reaction 
 
Prepanning. The stopped and centrifuged translation mix was pipetted to the previousely blocked 
immunotube (without target protein) and incubated by shaking for 1 h at 4 °C. 
Panning and Elution. The prepanned solution was transferred to the previousely prepared target coated 
and blocked immunotube and shaken for 1 h at 4 °C. The panning tube was subsequently washed 3 
times with 2 ml WBT-BSA-detergent. In order to elute RNA, 500 µl EB25 with 50 µg/ml S. cerevisiae 
RNA (2 µl of a 25 mg/ml stock) per ml, was added. After addition the sample was shaken for 5 min at 4 
°C. The eluate was directly pipetted into 1 ml lysis buffer of Roche RNA purification kit. A second elution 
step was performed and the RNA purified using the Roche high pure RNA isolation kit. 
Surface Panning using 96-well plates 
Preparation. The 96-well plates (Cert Maxisorb Nunc-Immuno Plates) was coated with 100 µl of 66 nM 
neutravidin in 1xTBS (3.3 µl from a 20 µM stock per ml). The plate was subsequently covered with 
plastic foil and incubated overnight at 4 °C. Four wells were used for each target protein. Wells were 
blocked with 250 µl 0.5 % BSA in 1xTBS for 1 h at RT while shaking. Wells were subsequently washed 
three times with 1xTBS and dried by removal of the supernatant. One-hundred µl of biotinylated target 
protein at ~ 1 µM in WBT-BSA-detergent was added to two wells and incubated by shaking for 1 h at 4 
°C. Just before panning is started, wells were washed three times with WBT-BSA-detergent. 
In vitro translation. The translation mix was pipetted according to pipetting scheme (table 3). Four µl 
library RNA à 2.5 µg/µl was added to the translation mix. The translation was carried out for exactly 8 
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min 30 sec at 37 °C. The reaction was stopped by addition of ice cold WBT-BSA-detergent buffer 
containing 12.5 µl Heparin (200 mg/ml stock) and sample was centrifuged at 20'000 g for 5 min at 4 °C. 
Prepanning. The stopped and centrifuged translation mix was pipetted to the previously blocked wells 
(without target protein) and incubated by shaking for 1 h at 4 °C. 
Panning and Elution. The prepanned solution was transferred to the previously prepared target coated 
wells and shaken for 1 h at 4 °C. The panning wells were subsequently washed 3 times with 250 µl 
WBT-BSA-detergent. In order to elute RNA, 100 µl EB25 with 50 µg/ml S. cerevisiae RNA (2 µl of a 25 
mg/ml stock) per ml, was added. The sample was shaken for 5 min at 4 °C. The eluate was directly 
pipetted into 200 µl lysis buffer of Roche RNA purification kit. A second elution step was performed and 
the RNA purified using the Roche high pure RNA isolation kit. 
Solution Panning 
Preparation. RNA free 2 ml tubes were blocked overnight with 1.8 ml 0.5 % BSA in 1xTBS at 4 °C. Three 
tubes were needed for each target protein.  For the prepanning, 20 µl of suspension of magnetic 
streptavidin coated beads (Streptavidin Magnetic Particles, Roche 11641778001 or Dynabeads® 
MyOneTM StreptavidinT1, Invitrogen 800.955.6288) are used (termed “beads” below). For the panning, 
20 µl/10 µl (1st and 2nd round/ 3rd and 4th round) of beads are used. For the 3rd and 4th round, 10 µl of 
suspension of beads are used to determine the selection background. The suspension was blocked in 
TBS-BSA (100 µl per 10 µl initial suspension) overnight (or for 2 h at RT) and washed once with 1 ml 
WBT-BSA-detergent prior to use. 
In vitro translation. The translation mix was pipetted according to the pipetting scheme (table 3). Four µl 
library RNA à 2.5 µg/µl were added to the translation mix. The translation was carried out for exactly 8 
min 30 sec at 37 °C. The reaction was stopped by adding ice cold WBT-BSA-detergent containing 12.5 
µl Heparin (200 mg/ml stock). The sample was centrifuged at 20'000 g for 5 min at 4 °C. 
Prepanning. The stopped and centrifuged translation mix was added to the magnetic streptavidin coated 
beads dedicated for the pre-panning (equivalent of 20 µl suspension) and incubated for 1 h at 4°C. 
Panning and Elution. The supernatant was transferred to a fresh tube and 1 µM/500 nM (1st and 2nd 
round/ 3rd and 4th round) of biotinylated target protein was added to the cleared supernatant. Incubation 
for 1 hour at 4°C (solution panning). In the 3rd and 4th round, a control omitting the biotinylated targets 
to check for background binding of the ribosomal complexes to the beads was included. The panning 
solution was added to the washed magnetic beads and incubated for 15 minutes. Afterwards the beads 
were washed three times with WBT-BSA-detergent. The washed beads were transferred to a fresh tube 
and the RNA was eluted using 100 µl EB25 with 50 µg/ml S. cerevisiae RNA (2 µl of a 25 mg/ml stock) 
per ml while Shaken for 5 min at 4 °C. The eluate was directly pipetted into 200 µl lysis buffer of Roche 
RNA purification kit. A second elution step was performed and the RNA purified using the Roche high 
pure RNA isolation kit. 
From Reverse Transcription to RNA preparation 
RNA Purification. Maximal 700 µl of the eluate mixed with lysis buffer was loaded to the column. The 
flow-through was discarded after spinning for 1 min at 8'000 g at 4 °C. This step was repeated until 
everything was loaded on the column. The column was washed with 500 µl buffer 1 and 500 µl buffer 
2. Afterwards 200 µl of buffer 2 was added to the column and centrifuged for 2 min at 13‘000 g. RNA 
was eluted with 30 µl elution buffer and centrifuged for 1 min at 8‘000 g. The eluted RNA can be stored 
at – 20 °C or used directly for reverse transcription. 
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Reverse Transcription. The eluted RNA was heated up to 70 °C for 10 min. The reverse transcription 
reaction was pipetted according the pipetting scheme (Table 4) and 8.75 µl RNA was added. The 
reverse transcription was carried out for 1 h at 50 °C and later used for PCR. 
 
2x Master mix 10 µl 
Primer rev (100 µM) 0.25 µl 
RNAsin (200 U/µl) 0.5 µl 
Affinity Script 0.5 µl 
Total 11.3 µl 
Table 4 Reverse transcription pipetting scheme for one reaction 
 
PCR on RT. The PCR reaction was mixed according to the pipetting scheme (Table 5) using the inner 
primers (EWT5/NC4S). 25 to 45 cycles were carried out (depending on the Ribosome Display round). 
The PCR product was purified on a 1.2 % agarose gel and extracted using the QIAquick Gel Extraction 
Kit (see manufacturer’s protocol). In the last round, the primers DARPin_fx_f and DARPin_fx_r were 
used instead of EWT5 and NC4S for cloning into a pBX_N_His_3C_vector, which was used for the 
expression of the DARPins in bacterial cells. 
 
H2O 34 µl 
DMSO 2.5 µl 
10x Buffer 5 µl 
dNTP (10 mM each) 2 µl 
Primer for (100 µM) 0.5 µl 
Primer rev (100 µM) 0.5 µl 
Vent polymerase 0.5 µl 
Mix with 5 µl template 45 µl 
Table 5 PCR pipetting scheme for one reaction 
 
PCR for Digestion. The PCR reaction was mixed according to the pipetting scheme (Table 5) using the 
inner primers (EWT5/NC4S). Twenty-five to forty-five cycles were carried out (depending on the 
Ribosome Display round). The PCR product was purified on a 1.2 % agarose gel and extracted using 
the QIAquick Gel Extraction Kit (see manufacturer’s protocol). 
Digestion of PCR product. The purified PCR product was digested using the restriction enzymes NcoI 
and HindIII for 1 h at 37 °C. The product was purified with the MinElute PCR purification Kit from QIAgen 
and directly eluted into the ligation mix. 
Preparation of fragments for ligation. DNA fragments containing RBS (ribosome binding site) and C-
terminal loop region were prepared by PCR on a pRDV- vector using the primers T7b_2 and 
pRDV_Nco_r or TolAk and pRDV_Hind_f for RBS-site and loop region, respectively. The fragments 
were digested with NcoI and HindIII respectively and purified on an 1.2 % agarose gel. 
Ligation with fragments to introduce RBS and loop region. The ligation mix was pipetted according to 
the pipetting scheme and incubated for 45 min at room temperature. The same amount of NcoI and 
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HindIII fragment were used, calculated by this formula (Loop-fragment: ca 300 bp, RBS- fragment: ca 
200 bp): 
 
 
PCR on ligation. The PCR reaction was mixed according to the pipetting scheme (table 5) using the 
outer primers (T7B.2/TolAk). Thirty to thirty-five cycles were carried out (depending on the Ribosome 
Display round). The PCR product was purified on a 1 % agarose gel and extracted using the QIAquick 
Gel Extraction Kit (see manufacturer’s protocol). 
PCR for Transcription. The PCR reaction was mixed according to the pipetting scheme (table 5) using 
the outer primers (T7B.2/TolAk). Thirty to thirty-five cycles were carried out (depending on the Ribosome 
Display round). Three µl of the PCR reaction was loaded on an analytical agarose gel (0.8 %). The 
remaining PCR mix was not purified and directly used for the transcription. 
Transcription. The transcription reaction was mixed according to the pipetting scheme (Table 6) using 
22.5 µl PCR product and carried out for 2-3 h at 37 °C. 
 
H2O 23.5 µl 
5x Buffer 20 µl 
NTPs (25 mM each) 28 µl 
RNAsin 2 µl 
T7 Pol 4 µl 
  
Table 6 Transcription pipetting scheme for one reaction 
 
Transcription with Promega kit. The PCR for transcription was done as described above, but with a two-
fold approach, thus doubling the PCR. The PCR was purified with the MinElute PCR purification Kit from 
QIAgen and eluted with 20 µl elution buffer. The transcription was carried out according to 
manufacturer’s protocol. 
RNA purification. 100 µl of UHP water and 200 µl of 6 M LiCl was added to the transcription mix and 
incubated on ice for 30 min. After centrifugation at 20'000 g for 30 min at 4 °C, the supernatant was 
discarded. The pellet was washed with 500 µl ice-cold 70 % EtOH and dried for 5 min at room 
temperature. The pellet was taken up in 200 µl ice cold UHP water and centrifuged at 20‘000 g for 5 min 
at 4 °C. The supernatant was transferred to a fresh eppendorf tube containing 20µl 3M NaOAc and 500 
µl of ice cold 100 % EtOH was added. The mixture was incubated at – 20 °C for at least 30 min or 
overnight and centrifuged at 20‘000g for 30 min at 4 °C. The supernatant was discarded and the pellet 
washed with 500 µl 70 % EtOH. The pelleted RNA was dried in a SpeedVac apparatus for 15 min and 
subsequently taken up in 30 µl ice cold UHP water. The concentration of the diluted (2 µl RNA in 500 µl 
UHP water) RNA was measured in a photo-spectrometer. One OD unit corresponds to 10 µg/µl stock 
RNA, e.g. OD*10 = concentration in µg/µl. The RNA was shock-frozen in liquid nitrogen and stored at -
20 °C (for long term storage at -80 °C). 
RNA purification with kit. The manufacturer’s protocol was followed and RNA concentration measured 
with a NanoDrop Spectrophotometer. 
 
ng (2) = (ng (1) * bp (1)) / bp (2) 
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4.4 Other methods 
4.4.1 Surface Plasmon Resonance (SPR) 
For all SPR measurements the ProteOn XPR36 interaction array system (BioRad) of the FGCZ 
(functional genomics centre Zurich) was used. Biotinylated GLIC and ELIC were purified as described 
above. After size exclusion chromatography the protein was immobilized via the ligand channels by 
binding of the avi-tag to a ProteOn™ NLC Sensor Chip until an RU of ca 600 was reached. The binders 
to be analysed, were purified with the same buffer as the corresponding target protein and loaded in 
different concentrations (0 to 600 mM) via the analyte channels at a flow rate of 30 μl/min. The ProteOn 
manager software from BioRad was used for analysis of the signals after referencing using the interspot 
regions. 
4.4.2 Crude cell extract 
Single clones (of scFvs, DARPins or nanobodies) were inoculated in 1.2 ml medium (TB or LB) 
supplemented with the appropriate antibiotics at 37 °C and shaken overnight at 200 rpm. 200 µl of this 
culture was taken to inoculate 900 µl medium and grown for 2-3 h at 37 °C, while shaking at 200 rpm 
prior to induction with 1 mM IPTG or 0.002 % arabinose. The binders were expressed at 20 °C overnight, 
the cells harvested (3000 g, 10 min, 4 °C) and frozen at –20 °C. The cells were lysed by resuspension 
in 50 µl PBS with 1 % detergent or by resuspension with 50 µl PER-II by vortexing. After incubation at 
room temperature for 30 min, 500 µl PBS was added and cell debris pelleted by centrifugation (3000 g, 
10 min, 4 °C). 
4.4.3 ELISA 
An ELISA plate (96-well or 384-well) was coated overnight at 4 °C with 67 nM neutravidin (in PBS, 100 
µl for 96-well plates or 20 µl for 384-well plates). The wells were blocked with 250 µl or 44 µl PBS 
containing 1 % BSA for 1h at room temperature. 300 nM of biotinylated membrane protein (100 µl or 20 
µl) was added to the wells in a PBS-BSA buffer containing the appropriate detergent and incubated for 
1 h at 4 °C under gentle agitation. After washing 3 times with PBS-detergent, the binders to fused to a 
His- or myc-tag were added in a PBS-BSA-detergent buffer and incubated while slightly shaking for 1 h 
at 4 °C. Subsequently the wells were washed and the primary antibody (100 µl or 20 µl in PBS-BSA-
detergent) was added and solution was incubated for 1 h at 4 °C. After 3 washing steps, the secondary 
antibody (conjugated with horse-radish peroxidase) was added (100 µl or 20 µl in PBS-BSA-detergent) 
and incubated for at least 30 min at 4 °C. After 4 washing steps, binding was detected by addition of a 
HRP- substrate. The reaction was stopped with 1 M HCL and absorbance was quantified at 450 nm in 
a Tecan infinite M1000 plate reader. 
4.4.4 RNA 
Constructs containing the gene of either the wild type or mutant channels preceded by the signal 
sequence of the chicken α7nAchR and a hemagglutinin- tag were cloned into a modified pTLN vector 
for expression in X. laevis oocytes. After linearization of the plasmid DNA by MluI, capped 
complementary RNA was transcribed with the mMessage mMachine kit (Ambion), purified with the 
RNeasy kit (Qiagen) and the concentration measured with a NanoDrop spectrophotometer. 
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4.5 Functional characterization of different GLIC and ELIC mutants 
4.5.1 Two- electrode voltage clamp (TEVC) 
Approximately 10 ng of RNA, coding for either the WT or mutant channels, was injected into 
defolliculated X.laevis oocytes. For expression, oocytes were incubated in Barth’s solution 
supplemented with 50 μg/ml Gentamycin at 16 °C. A surface expression assay was performed after 1, 
2 and 3 days after injection to analyse the highest expression levels. Two days after injection, two-
electrode voltage clamp measurements were performed at 20 °C (OC-725B, Warner Instrument Corp.), 
the voltage was clamped at -40 mV. For ELIC, maximal currents were recorded in a bath solution 
containing 10 mM Hepes (pH 7), 130 mM NaCl, 2mM KCl, 0.5 mM CaCl2 and 5 mM or 25 mM 
cysteamine. For GLIC the maximal currents were measured in a bath solution containing 10 mM Citrate 
(pH 4), 130 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl. Directly after recording of the maximal 
currents, the expression of the channels was analysed by a surface expression assay. 
4.5.2 X. laevis oocyte surface expression assay 
The X. laevis oocytes, previously used for TEVC, were subjected to a surface expression assay [131]. 
For that purpose the oocytes were placed in a 96-well plate (TPP, tissue culture testplate, flat bottom) 
and blocked in ND 96 solution containing 1 % BSA for at least 30 min at 4 °C. The hemagglutinin-tagged 
channels were labeled with 1 μg/ml rat monoclonal anti-HA antibody (3F10, Roche), in ND 96 solution 
containing 1% BSA for 1 h at 4°C and briefly washed 3x with ND96 solution at 4 °C. Subsequently 
oocytes were incubated with 0.16 μg/ml horseradish peroxidase–(HRP) coupled to a secondary 
antibody (HRP-conjugated goat anti-rat F(Ab)2 fragments (Jackson)), in ND96 solution containing 1% 
BSA for 30–60 min at 4°C. The oocytes were washed 5x for 10 min with ND96 solution at 4 °C and 
transferred to a white 96-well plate (flat bottom, Nunclon Delta Surface). The solution was aspirated, 30 
μL of Super Signal ELISA femto (Pierce) solutions 1 and 2 was added and luminescence was 
quantitated in a Tecan infinite M1000 plate reader. 
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